

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
18 December 2003 (18.12.2003)

PCT

(10) International Publication Number
WO 03/104438 A2

(51) International Patent Classification⁷: **C12N**
(21) International Application Number: **PCT/US03/19741**
(22) International Filing Date: **10 June 2003 (10.06.2003)**
(25) Filing Language: **English**
(26) Publication Language: **English**

(30) Priority Data:
60/388,075 **11 June 2002 (11.06.2002)** **US**

(71) Applicant (*for all designated States except US*): **AVALON PHARMACEUTICALS, INC.** [US/US]; 20358 Seneca Meadows Parkway, Germantown, MD 20876 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **YOUNG, Paul, E.** [US/US]; 207 Beckwith Street, Gaithersburg, MD 20870 (US). **EBNER, Reinhard** [US/US]; 9906 Shelburne Terrace #316, Gaithersburg, MD 20878 (US).

(74) Agents: **GRANT, Alan, J.** et al.; Carella, Byrne, Bain, Gilfillan, Cecchi, Stewart & Olstein, 6 Becker Farm Road, Roseland, NJ 07068 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **CANCER-LINKED GENE AS TARGET FOR CHEMOTHERAPY**

(57) Abstract: Cancer-linked gene sequences, and derived amino acid sequences, are disclosed along with processes for assaying potential antitumor agents based on their modulation of the expression of these cancer-linked genes. Also disclosed are antibodies that react with the disclosed polypeptides and methods of using the antibodies to treat cancerous conditions, such as by using the antibody to target cancerous cells *in vivo* for purposes of delivering therapeutic agents thereto. Also described are methods of diagnosing using the gene sequences.

WO 03/104438 A2

THIS PAGE BLANK (USPTO)

CANCER-LINKED GENE AS TARGET FOR CHEMOTHERAPY

5

This application claims priority of U.S. Provisional Patent Application 60/388,075, filed 11 June 2002, the disclosure of which is hereby incorporated by reference in its entirety.

10

FIELD OF THE INVENTION

15

The present invention relates to methods of screening cancer-linked genes and expression products for involvement in the cancer initiation and facilitation process as a means of cancer diagnosis as well as the use of such genes for screening potential anti-cancer agents, including small organic compounds and other molecules, and development of therapeutic agents.

20

BACKGROUND OF THE INVENTION

25

Cancer-linked genes are valuable in that they indicate genetic differences between cancer cells and normal cells, such as where a gene is expressed in a cancer cell but not in a non-cancer cell, or where said gene is over-expressed or expressed at a higher level in a cancer as opposed to normal or non-cancer cell. In addition, the expression of such a gene in a normal cell but not in a cancer cell, especially of the same type of tissue, can indicate important functions in the cancerous process. For example, screening assays for novel drugs are based on the response of model cell based systems *in vitro* to treatment with specific compounds. Such genes are also useful in the diagnosis of cancer and the identification of a cell as cancerous. Gene activity is readily measured by measuring the rate of production of gene

30

35

products, such as RNAs and polypeptides encoded by such genes. Where genes encode cell surface proteins, appearance of, or alterations in, such proteins, as cell surface markers, are an indication of neoplastic activity. Some such screens rely on specific genes, such as oncogenes (or gene mutations). In accordance with the present invention, a cancer-linked gene has been identified and its putative amino acid sequence worked out. Such gene is useful in the diagnosing of cancer, the screening of anticancer agents and the treatment of cancer using such agents, especially in that these genes encode polypeptides that can act as markers, such as cell surface markers, thereby providing ready targets for anti-tumor agents such as antibodies, preferably antibodies complexed to cytotoxic agents, including apoptotic agents.

BRIEF SUMMARY OF THE INVENTION

In accordance with the present invention, there is provided herein a cancer specific gene, linked especially to breast cancer, or otherwise involved in the cancer initiating and facilitating process and the derived amino acid sequence thereof, including a number of different transcripts derived from said gene.

In one aspect, the present invention relates to a process for identifying an agent that modulates the activity of a cancer-related gene comprising:

(a) contacting a compound with a cell containing a gene that corresponds to a polynucleotide having a sequence selected from the group consisting of SEQ ID NO: 1, 2, 3 and 4 and under conditions promoting the expression of said gene; and

(b) detecting a difference in expression of said gene relative to when said compound is not present

thereby identifying an agent that modulates the activity of a cancer-related gene.

5 In various embodiments of such a process, the cell is a cancer cell and the difference in expression is a decrease in expression. Such polynucleotides may also include those that have sequences identical to SEQ ID NO: 1, 2, 3 and 4.

10 In another aspect, the present invention relates to a process for identifying an anti-neoplastic agent comprising contacting a cell exhibiting neoplastic activity with a compound first identified as a cancer related gene modulator using an assay process disclosed herein and detecting a decrease in said neoplastic activity after said contacting compared to when said contacting does not occur. Such neoplastic activity may include accelerated
15 cellular replication and/or metastasis, and the decrease in neoplastic activity preferably results from the death of the cell, or senescence, terminal differentiation or growth inhibition.

20 The present invention also relates to a process for identifying an anti-neoplastic agent comprising administering to an animal exhibiting a cancer condition an effective amount of an agent first identified according to a process of one of one of the assays disclosed according to the invention and detecting a decrease in said cancerous condition.

25 The present invention further relates to a process for determining the cancerous status of a cell, comprising determining an increase in the level of expression in said cell of at least one gene that corresponds to a polynucleotide having a sequence selected from the group consisting of SEQ ID NO: 1, 2, 3 and 4 wherein an elevated expression relative to a known non-
30 cancerous cell indicates a cancerous state or potentially cancerous state. Such elevated expression may be due to an increased copy number.

The present invention additionally relates to an isolated polypeptide, encoded by one of the polynucleotide transcripts disclosed herein, comprising an amino acid sequence homologous to an amino acid sequence selected from the group consisting of SEQ ID NO: 5 and 6 wherein any difference
5 between said amino acid sequence and the sequence of SEQ ID NO: 5 and 6 is due solely to conservative amino acid substitutions and wherein said isolated polypeptide comprises at least one immunogenic fragment. In a preferred embodiment, the present invention encompasses an isolated polypeptide comprising an amino acid sequence homologous to an amino
10 acid sequence selected from the group consisting of SEQ ID NO: 5 and 6.

The present invention also relates to an antibody that reacts with a polypeptide as disclosed herein, preferably a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 5 and
15 6. Such an antibody may be polyclonal, monoclonal, recombinant or synthetic in origin.

In one such embodiment, said antibody is associated, either covalently or non-covalently, with a cytotoxic agent, for example, an
20 apoptotic agent. Thus, the present invention relates to an immunoconjugate comprising an antibody of the invention and a cytotoxic agent.

The present invention also relates to a process for treating cancer
25 comprising contacting a cancerous cell with an agent having activity against an expression product encoded by a gene sequence selected from the group consisting of SEQ ID NO: 1, 2, 3 and 4. In one such embodiment, the cancerous cell is contacted *in vivo*. In another such embodiment, said agent has affinity for said expression product. In a preferred embodiment, such
30 agent is an antibody disclosed herein, such as an antibody that is specific or selective for, or otherwise reacts with, a polypeptide of the invention. In a

preferred embodiment, the expression product is a polypeptide incorporating an amino acid sequence selected from SEQ ID NO: 5 and 6.

5 The present invention further encompasses an immunogenic composition comprising a polypeptide disclosed herein, as well as compositions formed using antibodies specific for these polypeptides.

10 The present invention is also directed to uses of such compositions. Such uses include a method for treating cancer in an animal afflicted therewith comprising administering to said animal an amount of an immunogenic composition of one or more of the polypeptides disclosed herein where such amount is an amount sufficient to elicit the production of cytotoxic T lymphocytes specific for a polypeptide of the invention, preferably a polypeptide incorporating a sequence of SEQ ID NO: 5 and 6. In a preferred
15 embodiment, the animal to be so treated is a human patient.

DEFINITIONS

20 As used herein, the terms "portion," "segment," and "fragment," when used in relation to polypeptides, refer to a continuous sequence of residues, such as amino acid residues, which sequence forms a subset of a larger sequence. For example, if a polypeptide were subjected to treatment with any of the common endopeptidases, such as trypsin or chymotrypsin, the oligopeptides
25 resulting from such treatment would represent portions, segments or fragments of the starting polypeptide. When used in relation to a polynucleotides, such terms refer to the products produced by treatment of said polynucleotides with any of the common endonucleases.

30 As used herein, the term "isolated" means that the material is removed from its original environment (e.g., the natural environment if it is naturally occurring). It could also be produced recombinantly and subsequently purified.

For example, a naturally-occurring polynucleotide or polypeptide present in a living animal is not isolated, but the same polynucleotide or polypeptide, separated from some or all of the coexisting materials in the natural system, is isolated. Such polynucleotides, for example, those prepared recombinantly, could be part of a vector and/or such polynucleotides or polypeptides could be part of a composition, and still be isolated in that such vector or composition is not part of its natural environment. In one embodiment of the present invention, such isolated, or purified, polypeptide is useful in generating antibodies for practicing the invention, or where said antibody is attached to a cytotoxic or cytolytic agent, such as an apoptotic agent.

The term "percent identity" or "percent identical," when referring to a sequence, means that a sequence is compared to a claimed or described sequence after alignment of the sequence to be compared (the "Compared Sequence") with the described or claimed sequence (the "Reference Sequence"). The Percent Identity is then determined according to the following formula:

$$\text{Percent Identity} = 100 [1 - (C/R)]$$

wherein C is the number of differences between the Reference Sequence and the Compared Sequence over the length of alignment between the Reference Sequence and the Compared Sequence wherein (i) each base or amino acid in the Reference Sequence that does not have a corresponding aligned base or amino acid in the Compared Sequence and (ii) each gap in the Reference Sequence and (iii) each aligned base or amino acid in the Reference Sequence that is different from an aligned base or amino acid in the Compared Sequence, constitutes a difference; and R is the number of bases or amino acids in the Reference Sequence over the length of the alignment with the Compared Sequence with any gap created in the Reference Sequence also being counted as a base or amino acid.

If an alignment exists between the Compared Sequence and the Reference Sequence for which the percent identity as calculated above is about equal to or greater than a specified minimum Percent Identity then the Compared Sequence has the specified minimum percent identity to the
5 Reference Sequence even though alignments may exist in which the hereinabove calculated Percent Identity is less than the specified Percent Identity.

As known in the art "similarity" between two polypeptides is determined
10 by comparing the amino acid sequence and its conserved amino acid substitutes of one polypeptide to the sequence of a second polypeptide.

In accordance with the present invention, the term "DNA segment" or "DNA sequence" refers to a DNA polymer, in the form of a separate fragment
15 or as a component of a larger DNA construct, which has been derived from DNA isolated at least once in substantially pure form, i.e., free of contaminating endogenous materials and in a quantity or concentration enabling identification, manipulation, and recovery of the segment and its component nucleotide sequences by standard biochemical methods, for
20 example, using a cloning vector. Such segments are provided in the form of an open reading frame uninterrupted by internal nontranslated sequences, or introns, which are typically present in eukaryotic genes. Sequences of non-translated DNA may be present downstream from the open reading frame, where the same do not interfere with manipulation or expression of the coding
25 regions.

The term "coding region" refers to that portion of a gene which either naturally or normally codes for the expression product of that gene in its natural genomic environment, i.e., the region coding *in vivo* for the native
30 expression product of the gene. The coding region can be from a normal, mutated or altered gene, or can even be from a DNA sequence, or gene, wholly synthesized in the laboratory using methods well known to those of skill in the art of DNA synthesis.

In accordance with the present invention, the term "nucleotide sequence" refers to a heteropolymer of deoxyribonucleotides. Generally, DNA segments encoding the proteins provided by this invention are assembled
5 from cDNA fragments and short oligonucleotide linkers, or from a series of oligonucleotides, to provide a synthetic gene which is capable of being expressed in a recombinant transcriptional unit comprising regulatory elements derived from a microbial, eukaryotic or viral operon.

10 The term "expression product" means that polypeptide or protein that is the natural translation product of the gene and any nucleic acid sequence coding equivalents resulting from genetic code degeneracy and thus coding for the same amino acid(s).

15 The term "active fragment," when referring to a coding sequence, means a portion comprising less than the complete coding region whose expression product retains essentially the same biological function or activity as the expression product of the complete coding region.

The term "primer" means a short nucleic acid sequence that is paired
20 with one strand of DNA and provides a free 3'-OH end at which a DNA polymerase starts synthesis of a deoxyribonucleotide chain.

The term "promoter" means a region of DNA involved in binding of RNA polymerase to initiate transcription. The term "enhancer" refers to a region of
25 DNA that, when present and active, has the effect of increasing expression of a different DNA sequence that is being expressed, thereby increasing the amount of expression product formed from said different DNA sequence.

The term "open reading frame (ORF)" means a series of triplets coding
30 for amino acids without any termination codons and is a sequence (potentially) translatable into protein.

As used herein, reference to a "DNA sequence" includes both single stranded and double stranded DNA. Thus, the specific sequence, unless the context indicates otherwise, refers to the single strand DNA of such sequence, the duplex of such sequence with its complement (double stranded
5 DNA) and the complement of such sequence.

As used herein, "corresponding genes" refers to genes that encode an RNA that is at least 90% identical, preferably at least 95% identical, most preferably at least 98% identical, and especially identical, to an RNA encoded
10 by one of the nucleotide sequences disclosed herein (i.e., SEQ ID NO: 1, 2, 3 and 4). Such genes will also encode the same polypeptide sequence as any of the sequences disclosed herein, preferably SEQ ID NO: 1, 2, 3 and 4, but may include differences in such amino acid sequences where such differences are limited to conservative amino acid substitutions, such as
15 where the same overall three dimensional structure, and thus the same antigenic character, is maintained. Thus, amino acid sequences may be within the scope of the present invention where they react with the same antibodies that react with polypeptides comprising the sequences of SEQ ID NO: 5 and 6. A "corresponding gene" includes splice variants thereof.

20

The genes identified by the present disclosure are considered "cancer-related" genes, as this term is used herein, and include genes expressed at higher levels (due, for example, to elevated rates of expression, elevated extent of expression or increased copy number) in cancer cells relative to
25 expression of these genes in normal (i.e., non-cancerous) cells where said cancerous state or status of test cells or tissues has been determined by methods known in the art, such as by reverse transcriptase polymerase chain reaction (RT-PCR) as described in the Examples herein. In specific embodiments, this relates to the genes whose sequences correspond to the
30 sequences of SEQ ID NO: 1, 2, 3 and 4.

As used herein, the term "conservative amino acid substitutions" are defined herein as exchanges within one of the following five groups:

I. Small aliphatic, nonpolar or slightly polar residues:

Ala, Ser, Thr, Pro, Gly;

5 II. Polar, negatively charged residues and their amides:

Asp, Asn, Glu, Gln;

III. Polar, positively charged residues:

His, Arg, Lys;

IV. Large, aliphatic, nonpolar residues:

10 Met Leu, Ile, Val, Cys

V. Large, aromatic residues:

Phe, Tyr, Trp

15

DETAILED SUMMARY OF THE INVENTION

20 The present invention relates to processes for utilizing a nucleotide sequence for a cancer-linked gene, polypeptides encoded by such sequences and antibodies reactive with such polypeptides in methods of treating and diagnosing cancer, preferably breast cancer, and in carrying out screening assays for agents effective in reducing the activity of cancer-linked genes and thereby treating a cancerous condition.

25

The sequences disclosed herein incorporate various polynucleotide transcripts (SEQ ID NO: 1, 2, 3 and 4) and the derived amino acid sequence (SEQ ID NO: 5 and 6) from said transcripts are available as targets for chemotherapeutic agents, especially anti-cancer agents, including antibodies
30 specific for said polypeptides. The transcript for this gene is up in breast cancer and should encode a type I transmembrane protein with a large immunogenic extracellular domain. The gene disclosed herein is especially

characteristic of breast cancer, preferably Wilms tumor and soft tissue fibromatosis.

The cancer-related polynucleotide sequences disclosed herein
5 correspond to gene sequences whose expression is indicative of the
cancerous status of a given cell. Such sequences are substantially identical to
SEQ ID NO: 1, 2, 3 and 4, which represent different transcripts identified from
the GenBank EST database and which exhibit cancer-specific expression.
The polynucleotides of the invention are those that correspond to a sequence
10 of SEQ ID NO: 1, 2, 3 and 4. Such sequences have been searched within the
GenBank database, especially the EST database, with the following results:

15	Type:	cell-surface tumor antigen therapeutic antibody target
	Tissue:	breast cancer, soft tissue fibromatosis, Wilms tumor
20	AffyFragment-ID(s):	124040, 143095, 156021 KIAA1497 protein
	Accession(s):	AI885003, AI857396, AI015776
25	Unigene cluster-ID(s):	Hs.126085
	Chromosomal location:	3

The nucleotides and polypeptides, as gene products, used in the
30 processes of the present invention may comprise a recombinant polynucleotide
or polypeptide, a natural polynucleotide or polypeptide, or a synthetic
polynucleotide or polypeptide, or a recombinant polynucleotide or polypeptide.

Fragments of such polynucleotides and polypeptides as are disclosed
35 herein may also be useful in practicing the processes of the present invention.
For example, a fragment, derivative or analog of the polypeptide (SEQ ID NO: 5
and 6) may be (i) one in which one or more of the amino acid residues are

substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded by the genetic code, or (ii) one in which one or more of the amino acid residues includes a substituent group, or (iii) one in which the mature polypeptide is fused with another compound, such as a compound to increase the half-life of the polypeptide (for example, polyethylene glycol), or (iv) one in which the additional amino acids are fused to the mature polypeptide, such as a leader or secretory sequence or a sequence which is employed for purification of the mature polypeptide (such as a histidine hexapeptide) or a proprotein sequence. Such fragments, derivatives and analogs are deemed to be within the scope of those skilled in the art from the teachings herein.

In another aspect, the present invention relates to an isolated polypeptide, including a purified polypeptide, comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 5 and/or 6. In preferred embodiments, said isolated polypeptide comprises an amino acid sequence having sequence identity of at least 95%, preferably at least about 98%, and especially is identical to, the sequence of SEQ ID NO: 5 and/or 6. The present invention also includes isolated active fragments of such polypeptides where said fragments retain the biological activity of the polypeptide or where such active fragments are useful as specific targets for cancer treatment, prevention or diagnosis. Thus, the present invention relates to any polypeptides, or fragments thereof, with sufficient sequence homology to the sequences disclosed herein as to be useful in the production of antibodies that react with (i.e., are selective or specific for) the polypeptides of SEQ ID NO: 5 and 6 so as to be useful in targeting cells that exhibit such polypeptides, or fragments, on their surfaces, thereby providing targets for such antibodies and therapeutic agents associated with such antibodies.

The polynucleotides and polypeptides useful in practicing the processes of the present invention may likewise be obtained in an isolated or purified form. In addition, the polypeptide disclosed herein as being useful in practicing the

processes of the invention are believed to be surface proteins present on cells, such as cancerous cells. Precisely how such cancer-linked proteins are used in the processes of the invention may thus differ depending on the therapeutic approach used. For example, cell-surface proteins, such as receptors, are
5 desirable targets for cytotoxic antibodies that can be generated against the polypeptides disclosed herein.

The sequence information disclosed herein, as derived from the GenBank submissions, can readily be utilized by those skilled in the art to
10 prepare the corresponding full-length polypeptide by peptide synthesis. The same is true for either the polynucleotides or polypeptides disclosed herein for use in the methods of the invention.

The present invention relates to an isolated polypeptide, encoded by
15 one of the polynucleotide transcripts disclosed herein, comprising an amino acid sequence homologous to an amino acid sequence selected from the group consisting of SEQ ID NO: 5 and 6, wherein any difference between amino acid sequence in the isolated polypeptide and the sequence of SEQ ID NO: 5 and 6 is due solely to conservative amino acid substitutions and
20 wherein said isolated polypeptide comprises at least one immunogenic fragment. In a preferred embodiment, the present invention encompasses an isolated polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 5 and 6.

25 Methods of producing recombinant cells and vectors useful in preparing the polynucleotides and polypeptides disclosed herein are well known to those skilled in the molecular biology art. See, for example, Sambrook, et al., *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor, N.Y., (1989), Wu et al., *Methods in Gene Biotechnology* (CRC
30 Press, New York, NY, 1997), and *Recombinant Gene Expression Protocols*, in *Methods in Molecular Biology*, Vol. 62, (Tuan, ed., Humana Press, Totowa, NJ, 1997), the disclosures of which are hereby incorporated by reference.

In one aspect, the present invention relates to a process for identifying an agent that modulates the activity of a cancer-related gene comprising:

(a) contacting a compound with a cell containing a gene that corresponds to a polynucleotide having a sequence selected from the group consisting of SEQ ID NO: 1, 2, 3 and 4 and under conditions promoting the expression of said gene; and

(b) detecting a difference in expression of said gene relative to when said compound is not present

thereby identifying an agent that modulates the activity of a cancer-related gene.

In specific embodiments of such process the cell is a cancer cell and the difference in expression is a decrease in expression. Such polynucleotides may also include those that have sequences identical to SEQ ID NO: 1, 2, 3 and 4.

In another aspect, the present invention relates to a process for identifying an anti-neoplastic agent comprising contacting a cell exhibiting neoplastic activity with a compound first identified as a cancer related gene modulator using an assay process disclosed herein and detecting a decrease in said neoplastic activity after said contacting compared to when said contacting does not occur. Such neoplastic activity may include accelerated cellular replication and/or metastasis, and the decrease in neoplastic activity preferably results from the death of the cell.

25

The present invention also relates to a process for identifying an anti-neoplastic agent comprising administering to an animal exhibiting a cancer condition an effective amount of an agent first identified according to a process of one of one of the assays disclosed according to the invention and detecting a decrease in said cancerous condition.

30

In specific embodiments of the present invention, the genes useful for the invention comprise genes that correspond to polynucleotides having a sequence selected from SEQ ID NO: 1, 2, 3 and 4, or may comprise the sequence of any of the polynucleotides disclosed herein (where the latter are
5 cDNA sequences).

In accordance with the present invention, such assays rely on methods of determining the activity of the gene in question. Such assays are advantageously based on model cellular systems using cancer cell lines,
10 primary cancer cells, or cancerous tissue samples that are maintained in growth medium and treated with compounds at a single concentration or at a range of concentrations. At specific times after treatment, cellular RNAs are conveniently isolated from the treated cells or tissues, which RNAs are indicative of expression of selected genes. The cellular RNA is then divided
15 and subjected to differential analysis that detects the presence and/or quantity of specific RNA transcripts, which transcripts may then be amplified for detection purposes using standard methodologies, such as, for example, reverse transcriptase polymerase chain reaction (RT-PCR), etc. The presence or absence, or concentration levels, of specific RNA transcripts are
20 determined from these measurements. The polynucleotide sequences disclosed herein are readily used as probes for the detection of such RNA transcripts and thus the measurement of gene activity and expression.

The polynucleotides of the invention can include fully operational genes
25 with attendant control or regulatory sequences or merely a polynucleotide sequence encoding the corresponding polypeptide or an active fragment or analog thereof.

Because expression of the polynucleotide sequences disclosed herein
30 are specific to the cancerous state, useful gene modulation is downward modulation, so that, as a result of exposure to an antineoplastic agent identified by the screening assays herein, the corresponding gene of the

cancerous cell is expressed at a lower level (or not expressed at all) when exposed to the agent as compared to the expression when not exposed to the agent. For example, the gene sequences disclosed herein (SEQ ID NO: 1, 2, 3 and 4) correspond to a gene expressed at a higher level in cells of breast cancer than in normal breast cells. Thus, where said chemical agent causes this gene of the tested cell to be expressed at a lower level than the same genes of the reference, this is indicative of downward modulation and indicates that the chemical agent to be tested has anti-neoplastic activity.

10 In carrying out the assays disclosed herein, relative antineoplastic activity may be ascertained by the extent to which a given chemical agent modulates the expression of genes present in a cancerous cell. Thus, a first chemical agent that modulates the expression of a gene associated with the cancerous state (i.e., a gene corresponding to one or more of the polynucleotide transcripts disclosed herein) to a larger degree than a second chemical agent tested by the assays of the invention is thereby deemed to have higher, or more desirable, or more advantageous, anti-neoplastic activity than said second chemical agent.

20 The gene expression to be measured is commonly assayed using RNA expression as an indicator. Thus, the greater the level of RNA (for example, messenger RNA or mRNA) detected the higher the level of expression of the corresponding gene. Thus, gene expression, either absolute or relative, is determined by the relative expression of the RNAs encoded by such genes.

25 RNA may be isolated from samples in a variety of ways, including lysis and denaturation with a phenolic solution containing a chaotropic agent (e.g., trizol) followed by isopropanol precipitation, ethanol wash, and resuspension in aqueous solution; or lysis and denaturation followed by isolation on solid support, such as a Qiagen resin and reconstitution in aqueous solution; or lysis and denaturation in non-phenolic, aqueous solutions followed by enzymatic conversion of RNA to DNA template copies.

Normally, prior to applying the processes of the invention, steady state RNA expression levels for the genes, and sets of genes, disclosed herein will have been obtained. It is the steady state level of such expression that is affected by potential anti-neoplastic agents as determined herein. Such steady state levels of expression are easily determined by any methods that are sensitive, specific and accurate. Such methods include, but are in no way limited to, real time quantitative polymerase chain reaction (PCR), for example, using a Perkin-Elmer 7700 sequence detection system with gene specific primer probe combinations as designed using any of several commercially available software packages, such as Primer Express software., solid support based hybridization array technology using appropriate internal controls for quantitation, including filter, bead, or microchip based arrays, solid support based hybridization arrays using, for example, chemiluminescent, fluorescent, or electrochemical reaction based detection systems.

The gene expression indicative of a cancerous state need not be characteristic of every cell of a given tissue. Thus, the methods disclosed herein are useful for detecting the presence of a cancerous condition within a tissue where less than all cells exhibit the complete pattern. Thus, for example, a selected gene corresponding to the sequence of SEQ ID NO: 1, may be found, using appropriate probes, either DNA or RNA, to be present in as little as 60% of cells derived from a sample of tumorous, or malignant, tissue. In a highly preferred embodiment, such gene pattern is found to be present in at least 100% of cells drawn from a cancerous tissue and absent from at least 100% of a corresponding normal, non-cancerous, tissue sample.

Expression of a gene may be related to copy number, and changes in expression may be measured by determining copy number. Such change in gene copy number may be determined by determining a change in expression of messenger RNA encoded by a particular gene sequence, especially that of SEQ ID NO: 1, 2, 3 and 4. Also in accordance with the present invention, said gene may be a cancer initiating or facilitating gene. In carrying out the

methods of the present invention, a cancer facilitating gene is a gene that, while not directly initiating tumor formation or growth, acts, such as through the actions of its expression product, to direct, enhance, or otherwise facilitate the progress of the cancerous condition, including where such gene acts
5 against genes, or gene expression products, that would otherwise have the effect of decreasing tumor formation and/or growth.

Although the expression of a gene corresponding to a sequence of SEQ ID NO: 1, 2, 3 and 4 may be indicative of a cancerous status for a given
10 cell, the mere presence of such a gene may not alone be sufficient to achieve a malignant condition and thus the level of expression of such gene may also be a significant factor in determining the attainment of a cancerous state. Thus, it becomes essential to also determine the level of expression of a gene as disclosed herein, including substantially similar sequences, as a separate
15 means of diagnosing the presence of a cancerous status for a given cell, groups of cells, or tissues, either in culture or *in situ*.

The level of expression of the polypeptides disclosed herein is also a measure of gene expression, such as polypeptides having sequence identical,
20 or similar to, any polypeptide encoded by a sequence of SEQ ID NO: 1, 2, 3 and 4, especially a polypeptide whose amino acid sequence is the sequence of SEQ ID NO: 5 and 6.

In accordance with the foregoing, the present invention specifically
25 contemplates a method for determining the cancerous status of a cell to be tested, comprising determining the level of expression in said cell of a gene that includes one of the nucleotide sequences selected from the sequences of SEQ ID NO: 1, 2, 3 and 4, including sequences substantially identical to said sequences, or characteristic fragments thereof, or the complements of any of
30 the foregoing and then comparing said expression to that of a cell known to be non-cancerous whereby the difference in said expression indicates that said cell to be tested is cancerous.

In accordance with the invention, although gene expression for a gene that includes as a portion thereof one of the sequences of SEQ ID NO: 1, 2, 3 and 4, is preferably determined by use of a probe that is a fragment of such nucleotide sequence, it is to be understood that the probe may be formed from a different portion of the gene. Expression of the gene may be determined by use of a nucleotide probe that hybridizes to messenger RNA (mRNA) transcribed from a portion of the gene other than the specific nucleotide sequence disclosed herein.

10

It should be noted that there are a variety of different contexts in which genes have been evaluated as being involved in the cancerous process. Thus, some genes may be oncogenes and encode proteins that are directly involved in the cancerous process and thereby promote the occurrence of cancer in an animal. In addition, other genes may serve to suppress the cancerous state in a given cell or cell type and thereby work against a cancerous condition forming in an animal. Other genes may simply be involved either directly or indirectly in the cancerous process or condition and may serve in an ancillary capacity with respect to the cancerous state. All such types of genes are deemed with those to be determined in accordance with the invention as disclosed herein. Thus, the gene determined by said process of the invention may be an oncogene, or the gene determined by said process may be a cancer facilitating gene, the latter including a gene that directly or indirectly affects the cancerous process, either in the promotion of a cancerous condition or in facilitating the progress of cancerous growth or otherwise modulating the growth of cancer cells, either *in vivo* or *ex vivo*. In addition, the gene determined by said process may be a cancer suppressor gene, which gene works either directly or indirectly to suppress the initiation or progress of a cancerous condition. Such genes may work indirectly where their expression alters the activity of some other gene or gene expression product that is itself directly involved in initiating or facilitating the progress of a cancerous condition. For example, a gene that encodes a polypeptide,

20
25
30

either wild or mutant in type, which polypeptide acts to suppress of tumor suppressor gene, or its expression product, will thereby act indirectly to promote tumor growth.

5 As noted previously, polynucleotides encoding the same proteins as any of SEQ ID NO: 1, 2, 3 and 4, regardless of the percent identity of such sequences, are also specifically contemplated by any of the methods of the present invention that rely on any or all of said sequences, regardless of how they are otherwise described or limited. Thus, any such sequences are
10 available for use in carrying out any of the methods disclosed according to the invention. Such sequences also include any open reading frames, as defined herein, present within the sequence of SEQ ID NO: 1, 2, 3 and 4.

 Because a gene disclosed according to the invention "corresponds to"
15 a polynucleotide having a sequence of SEQ ID NO: 1, 2, 3 and 4, said gene encodes an RNA (processed or unprocessed, including naturally occurring splice variants and alleles) that is at least 90% identical, preferably at least 95% identical, most preferably at least 98% identical to, and especially identical to, an RNA that would be encoded by, or be complementary to, such
20 as by hybridization with, a polynucleotide having the indicated sequence. In addition, genes including sequences at least 90% identical to a sequence selected from SEQ ID NO: 1, 2, 3 and 4, preferably at least about 95% identical to such a sequence, more preferably at least about 98% identical to such sequence and most preferably comprising such sequence are
25 specifically contemplated by all of the processes of the present invention. Sequences encoding the same proteins as any of these sequences, regardless of the percent identity of such sequences, are also specifically contemplated by any of the methods of the present invention that rely on any or all of said sequences, regardless of how they are otherwise described or
30 limited. The polynucleotide sequences of the invention also include any open reading frames, as defined herein, present within any of the sequences of SEQ ID NO: 1, 2, 3 and 4.

The sequences disclosed herein may be genomic in nature and thus represent the sequence of an actual gene, such as a human gene, or may be a cDNA sequence derived from a messenger RNA (mRNA) and thus represent contiguous exonic sequences derived from a corresponding genomic sequence, or they may be wholly synthetic in origin for purposes of practicing the processes of the invention. Because of the processing that may take place in transforming the initial RNA transcript into the final mRNA, the sequences disclosed herein may represent less than the full genomic sequence. They may also represent sequences derived from ribosomal and transfer RNAs. Consequently, the gene as present in the cell (and representing the genomic sequence) and the polynucleotide transcripts disclosed herein, including cDNA sequences, may be identical or may be such that the cDNAs contain less than the full genomic sequence. Such genes and cDNA sequences are still considered "corresponding sequences" (as defined elsewhere herein) because they both encode the same or related RNA sequences (i.e., related in the sense of being splice variants or RNAs at different stages of processing). Thus, by way of non-limiting example only, a gene that encodes an RNA transcript, which is then processed into a shorter mRNA, is deemed to encode both such RNAs and therefore encodes an RNA complementary to (using the usual Watson-Crick complementarity rules), or that would otherwise be encoded by, a cDNA (for example, a sequence as disclosed herein). Thus, the sequences disclosed herein correspond to genes contained in the cancerous cells (here, breast cancer) and are used to determine gene activity or expression because they represent the same sequence or are complementary to RNAs encoded by the gene. Such a gene also includes different alleles and splice variants that may occur in the cells used in the methods of the invention, such as where recombinant cells are used to assay for anti-neoplastic agents and such cells have been engineered to express a polynucleotide as disclosed herein, including cells that have been engineered to express such polynucleotides at a higher level than is found in non-engineered cancerous cells or where such recombinant cells

express such polynucleotides only after having been engineered to do so. Such engineering includes genetic engineering, such as where one or more of the polynucleotides disclosed herein has been inserted into the genome of such cell or is present in a vector.

5

Such cells, especially mammalian cells, may also be engineered to express on their surfaces one or more of the polypeptides of the invention for testing with antibodies or other agents capable of masking such polypeptides and thereby removing the cancerous nature of the cell. Such engineering
10 includes both genetic engineering, where the genetic complement of the cells is engineered to express the polypeptide, as well as non-genetic engineering, whereby the cell has been physically manipulated to incorporate a polypeptide of the invention in its plasma membrane, such as by direct insertion using chemical and/or other agents to achieve this result.

15

In accordance with the foregoing, the present invention includes anti-cancer agents that are themselves either polypeptides, or small chemical entities, that affect the cancerous process, including initiation, suppression or facilitation of tumor growth, either *in vivo* or *ex vivo*. Said cancer modulating
20 agent will have the effect of decreasing gene expression.

The present invention thus also relates to a method for treating cancer comprising contacting a cancerous cell with an agent having activity against an expression product encoded by a gene or polynucleotide sequence as
25 disclosed herein, such as one having, or corresponding to, the nucleotide sequence of SEQ ID NO: 1, 2, 3 and 4. The present invention also relates to a process for treating cancer comprising contacting a cancerous cell with an agent having activity against an expression product encoded by a gene or polynucleotide sequence corresponding to a sequence selected from the
30 group consisting of SEQ ID NO: 1, 2, 3 and 4. In one such embodiment, the cancerous cell is contacted *in vivo*. In another such embodiment, said agent has affinity for said expression product. In a preferred embodiment, such

agent is an antibody disclosed herein, such as an antibody that is specific or selective for, or otherwise reacts with, a polypeptide of the invention. In a preferred embodiment, the expression product is a polypeptide incorporating an amino acid sequence selected from SEQ ID NO: 5 and 6.

5

The present invention is also directed to such uses of the compositions of polypeptides and antibodies disclosed herein. Such uses include a process for treating cancer in an animal afflicted therewith comprising administering to said animal an amount of an immunogenic composition of one or more of the polypeptides disclosed herein where such amount is an amount sufficient to elicit the production of cytotoxic T lymphocytes specific for a polypeptide of the invention, preferably a polypeptide incorporating a sequence of SEQ ID NO: 5 and 6. In a preferred embodiment, the animal to be so treated is a human patient.

15

The proteins encoded by the genes disclosed herein due to their expression, or elevated expression, in cancer cells, represent highly useful therapeutic targets for "targeted therapies" utilizing such affinity structures as, for example, antibodies coupled to some cytotoxic agent. In such methodology, it is advantageous that nothing need be known about the endogenous ligands or binding partners for such cell surface molecules. Rather, an antibody or equivalent molecule that can specifically recognize the cell surface molecule (which could include an artificial peptide, a surrogate ligand, and the like) that is coupled to some agent that can induce cell death or a block in cell cycling offers therapeutic promise against these proteins. Thus, such approaches include the use of so-called suicide "bullets" against intracellular proteins. For example, monoclonal antibodies may readily be produced by methods well known in the art, for example, the method of Kohler and Milstein (see: *Nature*, 256:495 (1975)).

30

With the advent of methods of molecular biology and recombinant technology, it is now possible to produce antibody molecules by recombinant

means and thereby generate gene sequences that code for specific amino acid sequences found in the polypeptide structure of the antibodies. Such antibodies can be produced by either cloning the gene sequences encoding the polypeptide chains of said antibodies or by direct synthesis of said polypeptide chains, with *in vitro* assembly of the synthesized chains to form active tetrameric (H_2L_2) structures with affinity for specific epitopes and antigenic determinants. This has permitted the ready production of antibodies having sequences characteristic of neutralizing antibodies from different species and sources.

10 Regardless of the source of the antibodies, or how they are recombinantly constructed, or how they are synthesized, *in vitro* or *in vivo*, using transgenic animals, such as cows, goats and sheep, using large cell cultures of laboratory or commercial size, in bioreactors or by direct chemical synthesis employing no living organisms at any stage of the process, all antibodies have a similar overall 3 dimensional structure. This structure is often given as H_2L_2 and refers to the fact that antibodies commonly comprise 2 light (L) amino acid chains and 2 heavy (H) amino acid chains. Both chains have regions capable of interacting with a structurally complementary antigenic target. The regions interacting with the target are referred to as "variable" or "V" regions and are characterized by differences in amino acid sequence from antibodies of different antigenic specificity.

25 The variable regions of either H or L chains contains the amino acid sequences capable of specifically binding to antigenic targets. Within these sequences are smaller sequences dubbed "hypervariable" because of their extreme variability between antibodies of differing specificity. Such hypervariable regions are also referred to as "complementarity determining regions" or "CDR" regions. These CDR regions account for the basic specificity of the antibody for a particular antigenic determinant structure.

30

The CDRs represent non-contiguous stretches of amino acids within the variable regions but, regardless of species, the positional locations of

these critical amino acid sequences within the variable heavy and light chain regions have been found to have similar locations within the amino acid sequences of the variable chains. The variable heavy and light chains of all antibodies each have 3 CDR regions, each non-contiguous with the others
5 (termed L1, L2, L3, H1, H2, H3) for the respective light (L) and heavy (H) chains. The accepted CDR regions have been described by Kabat et al., *J. Biol. Chem.* **252**:6609-6616 (1977).

In all mammalian species, antibody polypeptides contain constant (i.e.,
10 highly conserved) and variable regions, and, within the latter, there are the CDRs and the so-called "framework regions" made up of amino acid sequences within the variable region of the heavy or light chain but outside the CDRs.

15 The antibodies disclosed according to the invention may also be wholly synthetic, wherein the polypeptide chains of the antibodies are synthesized and, possibly, optimized for binding to the polypeptides disclosed herein as being receptors. Such antibodies may be chimeric or humanized antibodies and may be fully tetrameric in structure, or may be dimeric and comprise only
20 a single heavy and a single light chain. Such antibodies may also include fragments, such as Fab and F(ab₂)' fragments, capable of reacting with and binding to any of the polypeptides disclosed herein as being receptors.

In one aspect, the present invention relates to immunoglobulins, or
25 antibodies, as described herein, that react with, especially where they are specific for, the polypeptides having amino acid sequences as disclosed herein, preferably those having an amino acid sequence of one of SEQ ID NO: 5 and 6. Such antibodies may commonly be in the form of a composition, especially a pharmaceutical composition. Such antibodies, by themselves,
30 may have therapeutic value in that they are able to bind to, and thereby tie up, surface sites on cancerous cells. Where such sites have some type of function to perform (i.e., where they are surface enzymes, or channel

structures, or structures that otherwise facilitate, actively or passively, the transport of nutrients and other vital materials to the cell. Such nutrients serve to facilitate the growth and replication of the cell and molecules that bind to such sites and thereby interfere with such activities can prove to have a therapeutic effect in that the result of such binding is to remove sources of nutrients from such cells, thereby interfering with growth and replication. In like manner, such binding may serve to remove vital enzyme activities from the cell's functional repertoire, thereby also interfering with viability and/or the ability of the cell to multiply or metastasize. In addition, by binding to such surface sites, the antibodies may serve to prevent the cells from reacting to environmental agents, such as cytokines and the like, that may facilitate growth, replication and metastasis, thereby further reducing the cancerous status of such cell and ameliorating the cancerous condition in a patient, even without proving fatal to the cell or cells so affected.

The methods of the present invention also include processes wherein the cancer cell is contacted *in vivo* as well as *ex vivo* with an agent that comprises a portion, or is part of an overall molecular structure, having affinity for an expression product of a gene corresponding to a polynucleotide sequence as disclosed herein, preferably where the expression product is a cell surface structure, most preferably a polypeptide as disclosed herein, such as one that comprises an amino acid sequence of SEQ ID NO: 5 and 6. In one such embodiment, said portion having affinity for said expression product is an antibody, especially where said expression product is a polypeptide or oligopeptide or comprises an oligopeptide portion, or comprises a polypeptide.

In another aspect, the present invention also relates to an antibody that reacts with a polypeptide as disclosed herein, preferably a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 5 and 6. Such an antibody may be polyclonal, monoclonal, recombinant or synthetic in origin. In one such embodiment, said antibody is associated, either covalently or non-covalently, with a cytotoxic agent, for example, an apoptotic agent. It is thus contemplated that the antibody acts a

targeted vector for guiding an associated therapeutic agent to a cancerous cell, such as a cell expressing a polypeptide homologous to, if not identical to, a polypeptide as disclosed herein.

5 Where the cytotoxic agent is itself a polypeptide, said may be linked directly to an antibody specific for a surface target on a cancer cell, such as where the polypeptide represents an extension of the amino acid chain of the antibody. In alternative embodiments, such molecules may be covalently linked through a linker sequence of long or short duration, such as an amino
10 acid sequence of 5 to 10 residues in length. Where the cytotoxic agents is some small organic molecule, such as a small organic compound, or some type of apoptotic agent, this may be covalently bonded to the antibody molecule or may be attached by some other type of non-covalent linkage, including hydrophobic and electrostatic linkages. Methods for forming such
15 linkages, especially covalent linkages, are well known to those skilled in the art.

 The antibodies disclosed herein may also serve as targeting vectors for much larger structures, such as liposomes. In one such embodiment, an
20 antibody is part of, or otherwise linked to, or associated with, a membranous structure, preferably a liposome or possibly some type of cellular organelle, which acts as a reservoir for a cytotoxic agent, such as ricin. The antibody then acts to target said liposome to a cancerous tissue in an animal, whereupon the liposome provides a source of cytotoxic agents for localized
25 treatment of a solid tumor or other type of neoplasm.

 The present invention further encompasses an immunogenic composition comprising a polypeptide disclosed herein, as well as compositions formed using antibodies specific for these polypeptides.

30

 Methods well known in the art for making formulations are found in, for example, *Remington: The Science and Practice of Pharmacy*, (19th ed.) Ed.

A.R. Gennaro, 1995, Mack Publishing Company, Easton, PA. Formulations for parenteral administration may, for example, contain excipients, sterile water, or saline, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, or hydrogenated naphthalenes. Biocompatible, biodegradable lactide polymer, lactide/glycolide copolymer, or polyoxyethylene-polyoxypropylene copolymers may be used to control the release of the compounds. Other potentially useful parenteral delivery systems for agonists of the invention include ethylenevinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes. Formulations for inhalation may contain excipients, or example, lactose, or may be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or may be oily solutions for administration in the form of nasal drops, or as a gel. It should be noted that, where the therapeutic agent to be administered is an immunoconjugate, these sometimes contain chemical linkages that are somewhat labile in aqueous media and therefore must be stored prior to administration in a more stable environment, such as in the form of a lyophilized powder.

Such an agent can be a single molecular structure, comprising both affinity portion and anti-cancer activity portions, wherein said portions are derived from separate molecules, or molecular structures, possessing such activity when separated and wherein such agent has been formed by combining said portions into one larger molecular structure, such as where said portions are combined into the form of an adduct. Said anti-cancer and affinity portions may be joined covalently, such as in the form of a single polypeptide, or polypeptide-like, structure or may be joined non-covalently, such as by hydrophobic or electrostatic interactions, such structures having been formed by means well known in the chemical arts. Alternatively, the anti-cancer and affinity portions may be formed from separate domains of a single molecule that exhibits, as part of the same chemical structure, more than one activity wherein one of the activities is against cancer cells, or tumor formation

or growth, and the other activity is affinity for an expression product produced by expression of genes related to the cancerous process or condition.

5 In one embodiment of the present invention, a chemical agent, such as a protein or other polypeptide, is joined to an agent, such as an antibody, having affinity for an expression product of a cancerous cell, such as a polypeptide or protein encoded by a gene related to the cancerous process, preferably a gene as disclosed herein according to the present invention, most preferably a polypeptide sequence disclosed herein. Thus, where the
10 presence of said expression product is essential to tumor initiation and/or growth, binding of said agent to said expression product will have the effect of negating said tumor promoting activity. In one such embodiment, said agent is an apoptosis-inducing agent that induces cell suicide, thereby killing the cancer cell and halting tumor growth.

15 Other genes within the cancer cell that are regulated in a manner similar to that of the genes disclosed herein and thus change their expression in a coordinated way in response to chemical compounds represent genes that are located within a common metabolic, signaling, physiological, or functional pathway so that by analyzing and identifying such commonly
20 regulated groups of genes (groups that include the gene, or similar sequences, disclosed according to the invention, one can (a) assign known genes and novel genes to specific pathways and (b) identify specific functions and functional roles for novel genes that are grouped into pathways with genes for which their functions are already characterized or described. For
25 example, one might identify a group of 10 genes, at least one of which is the gene as disclosed herein, that change expression in a coordinated fashion and for which the function of one, such as the polypeptide encoded by the sequence disclosed herein, is known then the other genes are thereby implicated in a similar function or pathway and may thus play a role in the
30 cancer-initiating or cancer-facilitating process. In the same way, if a gene were found in normal cells but not in cancer cells, or happens to be expressed at a higher level in normal as opposed to cancer cells, then a similar

conclusion may be drawn as to its involvement in cancer, or other diseases. Therefore, the processes disclosed according to the present invention at once provide a novel means of assigning function to genes, i.e. a novel method of functional genomics, and a means for identifying chemical compounds that
5 have potential therapeutic effects on specific cellular pathways. Such chemical compounds may have therapeutic relevance to a variety of diseases outside of cancer as well, in cases where such diseases are known or are demonstrated to involve the specific cellular pathway that is affected.

10 The polypeptides disclosed herein, preferably those of SEQ ID NO: 5 and 6, also find use as vaccines in that, where the polypeptide represents a surface protein present on a cancer cell, such polypeptide may be administered to an animal, especially a human being, for purposes of activating cytotoxic T lymphocytes (CTLs) that will be specific for, and act to
15 lyze, cancer cells in said animal. Where used as vaccines, such polypeptides are present in the form of a pharmaceutical composition. The present invention may also employ polypeptides that have the same, or similar, immunogenic character as the polypeptides of SEQ ID NO: 5 and 6 and thereby elicit the same, or similar, immunogenic response after administration
20 to an animal, such as an animal at risk of developing cancer, or afflicted therewith. Thus, the polypeptides disclosed according to the invention will commonly find use as immunogenic compositions.

Expression of a gene corresponding to a polynucleotide disclosed
25 herein, when in normal tissues, may indicate a predisposition towards development of breast cancer. The encoded polypeptide might then present a potentially useful cell surface target for therapeutic molecules such as cytolytic antibodies, or antibodies attached to cytotoxic, or cytolytic, agents. .

30 The present invention specifically contemplates use of antibodies against the polypeptides encoded by the polynucleotides corresponding to the genes disclosed herein, whereby said antibodies are conjugates to one or

more cytotoxic agents so that the antibodies serve to target the conjugated immunotoxins to a region of cancerous activity, such as a solid tumor. For many known cytotoxic agents, lack of selectivity has presented a drawback to their use as therapeutic agents in the treatment of malignancies. For example, the class of two-chain toxins, consisting of a binding subunit (or B-chain) linked to a toxic subunit (A-chain) are extremely cytotoxic. Thus, such agents as ricin, a protein isolated from castor beans, kills cells at very low concentrations (even less than 10^{-11} M) by inactivating ribosomes in said cells (see, for example, Lord et al., Ricin: structure, mode of action, and some current applications. *Faseb J*, **8**: 201-208 (1994), and Blättler et al., Realizing the full potential of immunotoxins. *Cancer Cells*, **1**: 50-55 (1989)). While isolated A-chains of protein toxins that functionally resemble ricin A-chain are only weakly cytotoxic for intact cells (in the concentration range of 10^{-7} to 10^{-6} M), they are very potent cytotoxic agents inside the cells. Thus, a single molecule of the A-subunit of diphtheria toxin can kill a cell once inside (see: Yamaizumi et al., One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell. *Cell*, **15**: 245-250, 1978).

The present invention solves this selectivity problem by using antibodies specific for antigens present on cancer cells to target the cytotoxins to said cells. In addition, use of antibodies decreases toxicity because the antibodies are non-toxic until they reach the tumor and, because the cytotoxin is bound to the antibody, it is presented with less opportunity to cause damage to non-targeted tissues.

In addition, use of such antibodies alone can provide therapeutic effects on the tumor through the antibody-dependent cellular cytotoxic response (ADCC) and complement-mediated cell lysis mechanisms.

A number of recombinant immunotoxins (for example, consisting of Fv regions of cancer specific antibodies fused to truncated bacterial toxins) are well known (see, for example, Smyth et al., Specific targeting of chlorambucil to tumors with the use of monoclonal antibodies, *J. Natl. Cancer Inst.*,

76(3):503-510 (1986); Cho et al., Single-chain Fv/folate conjugates mediate efficient lysis of folate-receptor-positive tumor cells, *Bioconjug. Chem.*, 8(3):338-346 (1997)). As noted in the literature, these may contain, for example, a truncated version of *Pseudomonas* exotoxin as a toxic moiety but
5 the toxin is modified in such a manner that by itself it does not bind to normal human cells, but it retains all other functions of cytotoxicity. Here, recombinant antibody fragments target the modified toxin to cancer cells which are killed, such as by direct inhibition of protein synthesis, or by concomitant induction of apoptosis. Cells that are not recognized by the antibody fragment, because
10 they do not carry the cancer antigen, are not affected. Good activity and specificity has been observed for many recombinant immunotoxins in *in vitro* assays using cultured cancer cells as well as in animal tumor models. Ongoing clinical trials provide examples where the promising pre-clinical data correlate with successful results in experimental cancer therapy. (see, for
15 example, Brinkmann U., Recombinant antibody fragments and immunotoxin fusions for cancer therapy, *In Vivo* (2000) 14:21-27).

While the safety of employing immunoconjugates in humans has been established, *in vivo* therapeutic results have been less impressive. Because
20 clinical use of mouse MAbs in humans is limited by the development of a foreign anti-globulin immune response by the human host, genetically engineered chimeric human-mouse MAbs have been developed by replacing the mouse Fc region with the human constant region. In other cases, the mouse antibodies have been "humanized" by replacing the framework regions
25 of variable domains of rodent antibodies by their human equivalents. Such humanized and engineered antibodies can even be structurally arranged to have specificities and effector functions determined by design and which characteristics do not appear in nature. The development of bispecific antibodies, having different binding ends so that more than one antigenic site
30 can be bound, have proven useful in targeting cancer cells. Thus, such antibody specificity has been improved by chemical coupling to various agents such as bacterial or plant toxins, radionuclides or cytotoxic drugs and other agents. (see, for example, Bodey, B. et al). Genetically engineered

monoclonal antibodies for direct anti-neoplastic treatment and cancer cell specific delivery of chemotherapeutic agents. *Curr Pharm Des* (2000) Feb;6(3):261-76). See also, Garnett, M. C., Targeted drug conjugates: principles and progress. *Adv. Drug Deliv. Rev.* (2001 Dec 17) **53**(2):171-216;
5 Brinkmann et al., Recombinant immunotoxins for cancer therapy. *Expert Opin Biol Ther.* (2001) **1**(4):693-702.

Among the cytotoxic agents specifically contemplated for use as immunoconjugates according to the present invention are Calicheamicin, a
10 highly toxic enediyne antibiotic isolated from *Micromonospora echinospora ssp. Calichensis*, and which binds to the minor groove of DNA to induce double strand breaks and cell death (see: Lee et al., Calicheamicins, a novel family of antitumor antibiotics. 1. Chemistry and partial structure of calicheamicin g₁. *J Am Chem Soc*, **109**: 3464-3466 (1987);
15 Zein et al., Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically, *Science*, **240**: 1198-1201 (1988)). Useful derivatives of the calicheamicins include mylotarg and 138H11-Cam θ . Mylotarg is an immunoconjugate of a humanized anti-CD33 antibody (CD33 being found in leukemic cells of most patients with acute myeloid leukemia)
20 and N-acetyl gamma colicheamicin dimethyl hydrazide, the latter of which is readily coupled to an antibody of the present invention (in place of the anti-CD33 but which can also be humanized by substitution of human framework regions into the antibody during production as described elsewhere herein) to form an immunoconjugate of the invention. (see: Hamann et al. Gemtuzumab
25 Ozogamicin, A Potent and Selective Anti-CD33 Antibody-Calicheamicin Conjugate for Treatment of Acute Myeloid Leukemia, *Bioconjug. Chem.* **13**, 47-58 (2002)) For use with 138H11-Cam θ , 138H11 is an anti- γ -glutamyl transferase antibody coupled to theta calicheamicin through a disulfide linkage and found useful *in vitro* against cultured renal cell carcinoma cells.
30 (see: Knoll et al., Targeted therapy of experimental renal cell carcinoma with a novel conjugate of monoclonal antibody 138H11 and calicheamicin θ_1^I , *Cancer Res*, **60**: 6089-6094 (2000) The same linkage may be utilized to link

this cytotoxic agent to an antibody of the present invention, thereby forming a targeting structure for breast cancer cells.

Also useful in forming the immunoconjugates of the invention is DC1, a
5 disulfide-containing analog of adozelesin, that kills cells by binding to the
minor groove of DNA, followed by alkylation of adenine bases. Adozelesin is a
structural analog of CC-1065, an anti-tumor antibiotic isolated from microbial
fermentation of *Streptomyces zelensis*, and is about 1,000 fold more toxic to
10 cultured cell lines than other DNA interacting agents, such as cis-platin and
doxorubicin. This agent is readily linked to antibodies through the disulfide
bond of adozelesin. (see: Chari et al., Enhancement of the selectivity and
antitumor efficacy of a CC-1065 analogue through immunoconjugate
formation, *Cancer Res*, **55**: 4079-4084 (1995)).

15 Maytansine, a highly cytotoxic microtubular inhibitor isolated from the
shrub *Maytenus serrata* found to have little value in human clinical trials, is
much more effective in its derivatized form, denoted DM1, containing a
disulfide bond to facilitate linkage to antibodies, is up to 10-fold more cytotoxic
(see: Chari et al., Immunoconjugates containing novel maytansinoids:
20 promising anticancer drugs, *Cancer Res*, **52**: 127-131 (1992)). These same *in*
vitro studies showed that up to four DM1 molecules could be linked to a single
immunoglobulin without destroying the binding affinity. Such conjugates have
been used against breast cancer antigens, such as the *neu*/HER2/*erbB-2*
antigen. (see: Goldmacher et al., Immunogen, Inc., (2002) *in press*); also see
25 Liu, C. et al., Eradication of large colon tumor xenografts by targeted delivery
of maytansinoids, *Proc. Natl. Acad. Sci. USA*, **93**, 8618-8623 (1996)). For
example, Liu et al. (1996) describes formation of an immunoconjugate of the
maytansinoid cytotoxin DM1 and C242 antibody, a murine IgG1
immunoglobulin, available from Pharmacia and which has affinity for a mucin-
30 like glycoprotein variably expressed by human colorectal cancers. The latter
immunoconjugate was prepared according to Chari et al., *Cancer Res.*,
52:127-131 (1992) and was found to be highly cytotoxic against cultured colon

cancer cells as well as showing anti-tumor effects *in vivo* in mice bearing subcutaneous COLO 205 human colon tumor xenografts using doses well below the maximum tolerated dose.

5 In addition, there are a variety of protein toxins (cytotoxic proteins), which include a number of different classes, such as those that inhibit protein synthesis: ribosome-inactivating proteins of plant origin, such as ricin, abrin, gelonin, and a number of others, and bacterial toxins such as pseudomonas exotoxin and diphtheria toxin.

10

 Another useful class is the one including taxol, taxotere, and taxoids. Specific examples include paclitaxel (taxol), its analog docetaxel (taxotere), and derivatives thereof. The first two are clinical drugs used in treating a number of tumors while the taxoids act to induce cell death by inhibiting the
15 de-polymerization of tubulin. Such agents are readily linked to antibodies through disulfide bonds without disadvantageous effects on binding specificity.

 In one instance, a truncated Pseudomonas exotoxin was fused to an
20 anti-CD22 variable fragment and used successfully to treat patients with chemotherapy-resistant hairy-cell leukemia. (see: Kreitman et al., Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia, *N Engl J Med*, 345: 241-247 (2001)) Conversely, the cancer-linked peptides of the present invention offer the opportunity to
25 prepare antibodies, recombinant or otherwise, against the appropriate antigens to target solid tumors, preferably those of malignancies of breast tissue, using the same or similar cytotoxic conjugates. Thus, many of the previously used immunoconjugates have been formed using antibodies against general antigenic sites linked to cancers whereas the antibodies
30 formed using the peptides disclosed herein are more specific and target the antibody-cytotoxic agent to a particular tissue or organ, thus further reducing toxicity and other undesirable side effects.

In accordance with the foregoing, a preferred embodiment includes where the cytotoxic agent is a calicheamicin, a maytansinoid, an adozelesin, DC1, a cytotoxic protein, a taxol, a taxotere, or a taxoid. In especially preferred embodiments, the calicheamicin is calicheamicin γ_1^1 ,
5 N-acetyl gamma calicheamicin dimethyl hydrazide or calicheamicin θ_1^1 , the maytansinoid is DM1, the cytotoxic protein is ricin, abrin, gelonin, pseudomonas exotoxin or diphtheria toxin, the taxol is paclitaxel, and the taxotere is docetaxel. .

10 In addition, the immunoconjugates formed using the antibodies prepared against the cancer-linked antigens disclosed herein can be formed by any type of chemical coupling. Thus, the cytotoxic agent of choice, along with the immunoglobulin, can be coupled by any type of chemical linkage, covalent or non-covalent, including electrostatic linkage, to form the
15 immunoconjugates of the present invention.

When used as immunoconjugates, the antitumor agents of the present invention represent a class of pro-drugs that are relatively non-toxic when first administered to an animal (due mostly to the stability of the
20 immunoconjugate), such as a human patient, but which are targeted by the conjugated immunoglobulin to a cancer cell where they then exhibit good toxicity. The tumor-related, associated, or linked, antigens, preferably those presented herein, serve as targets for the antibodies (monoclonal, recombinant, and the like) specific for said antigens. The end result is the
25 release of active cytotoxic agent inside the cell after binding of the immunoglobulin portion of the immunoconjugate.

The cited references describe a number of useful procedures for the chemical linkage of cytotoxic agents to immunoglobulins and the disclosures
30 of all such references cited herein are hereby incorporated by reference in their entirety. For other reviews see Ghetie et al., Immunotoxins in the therapy of cancer: from bench to clinic, *Pharmacol Ther*, **63**: 209-234 (1994), Pietersz

et al. The use of monoclonal antibody immunoconjugates in cancer therapy, *Adv Exp Med Biol*, **353**:169-179 (1994), and Pietersz, G. A. The linkage of cytotoxic drugs to monoclonal antibodies for the treatment of cancer, *Bioconjug Chem*, **1**:89-95 (1990).

5

Thus, the present invention provides highly useful cancer-associated antigens for generation of antibodies for linkage to a number of different cytotoxic agents which are already known to have some *in vitro* toxicity and possess chemical groups available for linkage to antibodies.

10

The present invention also relates to a process that comprises a method for producing a product, including generating test data, comprising identifying an agent according to one of the disclosed processes for identifying such an agent (i.e., the therapeutic agents identified according to the assay procedures disclosed herein) wherein said product is the data collected with respect to said agent as a result of said identification process, or assay, and wherein said data is sufficient to convey the chemical character and/or structure and/or properties of said agent. For example, the present invention specifically contemplates a situation whereby a user of an assay of the invention may use the assay to screen for compounds having the desired enzyme modulating activity and, having identified the compound, then conveys that information (i.e., information as to structure, dosage, etc) to another user who then utilizes the information to reproduce the agent and administer it for therapeutic or research purposes according to the invention.

For example, the user of the assay (user 1) may screen a number of test compounds without knowing the structure or identity of the compounds (such as where a number of code numbers are used the first user is simply given samples labeled with said code numbers) and, after performing the screening process, using one or more assay processes of the present invention, then imparts to a second user (user 2), verbally or in writing or some equivalent fashion, sufficient information to identify the compounds having a particular modulating activity (for example, the code number with the corresponding

results). This transmission of information from user 1 to user 2 is specifically contemplated by the present invention.

5 It should be cautioned that, in carrying out the procedures of the present invention as disclosed herein, whether to form immunoconjugates or screen for other antitumor agents using the genes and polypeptides disclosed herein, any reference to particular buffers, media, reagents, cells, culture conditions and the like are not intended to be limiting, but are to be read so as to include all related materials that one of ordinary skill in the art would
10 recognize as being of interest or value in the particular context in which that discussion is presented. For example, it is often possible to substitute one buffer system or culture medium for another and still achieve similar, if not identical, results. Those of skill in the art will have sufficient knowledge of such systems and methodologies so as to be able, without undue
15 experimentation, to make such substitutions as will optimally serve their purposes in using the methods and procedures disclosed herein.

The present invention will now be further described by way of the following non-limiting example. In applying the disclosure of the example, it
20 should be kept clearly in mind that other and different embodiments of the methods disclosed according to the present invention will no doubt suggest themselves to those of skill in the relevant art. The following example shows how a potential anti-neoplastic agent may be identified using one or more of the genes disclosed herein.

25

EXAMPLE

Determination of Gene Inhibitory Activity of an Anti-neoplastic Agent

30

SW480 cells are grown to a density of 10^5 cells/cm² in Leibovitz's L-15 medium supplemented with 2 mM L-glutamine (90%) and 10% fetal bovine serum. The cells are collected after treatment with 0.25% trypsin, 0.02%

EDTA at 37°C for 2 to 5 minutes. The trypsinized cells are then diluted with 30 ml growth medium and plated at a density of 50,000 cells per well in a 96 well plate (100 µl/well). The following day, cells are treated with either compound buffer alone, or compound buffer containing a chemical agent to be tested, for 5 24 hours. The media is then removed, the cells lysed and the RNA recovered using the RNeasy reagents and protocol obtained from Qiagen. RNA is quantitated and 10 ng of sample in 1 µl are added to 24 µl of Taqman reaction mix containing 1X PCR buffer, RNAsin, reverse transcriptase, nucleoside triphosphates, amplitaq gold, Tween 20, glycerol, bovine serum albumin 10 (BSA) and specific PCR primers and probes for a reference gene (18S RNA) and a test gene (Gene X). Reverse transcription is then carried out at 48°C for 30 minutes. The sample is then applied to a Perkin Elmer 7700 sequence detector and heat denatured for 10 minutes at 95°C. Amplification is performed through 40 cycles using 15 seconds annealing at 60°C followed by 15 a 60 second extension at 72°C and 30 second denaturation at 95°C. Data files are then captured and the data analyzed with the appropriate baseline windows and thresholds.

The quantitative difference between the target and reference gene is 20 then calculated and a relative expression value determined for all of the samples used. In this way, the ability of a chemotherapeutic agent to effectively and selectively reduce the activity of a cancer-specific gene is readily ascertained. The overall expression of the cancer-specific gene, as modulated by one chemical agent relative to another, is also determined. 25 Chemical agents having the most effect in reducing gene activity are thereby identified as the most anti-neoplastic.

References:

- 5 Walter A. Blättler and Ravi Chari: Drugs to enhance the therapeutic potency of anti-cancer antibodies: antibody-drug conjugates as tumor-activated prodrugs. In *Anticancer Agents - Frontiers in Cancer Chemotherapy* (Iwao Ojima, Gregory D. Vite, Karl-Heinz Altmann, Eds.), American Chemical Society, pp. 317-338 (2001).
- 10 Dan L. Longo, Patricia L. Duffey, John G. Gribben, Elaine S. Jaffe, Brendan D. Curti, Barry L. Gause, John E. Janik, Virginia M. Braman, Dixie Esseltine, Wyndham H. Wilson, Dwight Kaufman, Robert E. Wittes, Lee M. Nadler, and Walter J. Urbas: Combination chemotherapy followed by an Immunotoxin (Anti-B4-blocked Ricin) in patients with indolent lymphoma: results of a Phase II study. *Cancer J.* 6, 146-150 (2000).
- 15 Walter A. Blättler and John M. Lambert: Preclinical immunotoxin development. In *Monoclonal Antibody-Based Therapy of Cancer* (M. Grossbard, Ed.), Marcel Dekker, Inc. NY, NY, pp. 1-22 (1998).
- Ravi V. J. Chari: Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy. In *Advanced Drug Delivery Reviews*, Elsevier Science B.V., pp. 89-104 (1998).
- 20 David T. Scadden, David P. Schenkein, Zale Bernstein, Barry Luskey, John Doweiko, Anil Tulpule, and Alexandra M. Levine: Immunotoxin combined with chemotherapy for patients with AIDS-related Non-Hodgkin's Lymphoma. *Cancer* 83, 2580-2587 (1998).
- 25 Changnian Liu and Ravi VJ Chari: The development of antibody delivery systems to target cancer with highly potent maytansinoids. *Exp. Opi. Invest. Drugs* 6, 169-172 (1997).
- 30 A. C. Goulet, Viktor S. Goldmacher, John M. Lambert, C. Baron, Dennis C. Roy and E. Kouassi: Conjugation of blocked ricin to an anti-CD19 monoclonal antibody increases antibody-induced cell calcium mobilization and CD19 internalization. *Blood* 90, 2364-2375 (1997).
- Changnian Liu, John M. Lambert, Beverly A. Teicher, Walter A. Blättler, and Rosemary O'Connor: Cure of multidrug-resistant human B-cell lymphoma xenografts by combinations of anti-B4-blocked ricin and chemotherapeutic drugs. *Blood* 87, 3892-3898 (1996).
- 35 Rajeeva Singh, Lana Kats, Walter A. Blättler, and John M. Lambert: Formation of N-Substituted 2-Iminothiolanes when amino groups in proteins and peptides are modified by 2-Iminothiolane. *Anal. Biochem.* 236, 114-125 (1996).
- 40 Changnian Liu, B. Mitra Tadayoni, Lizabeth A. Bourret, Kristin M. Mattocks, Susan M. Derr, Wayne C. Widdison, Nancy L. Kedersha, Pamela D. Ariniello, Victor S. Goldmacher, John M. Lambert, Walter A. Blättler, and Ravi V.J.

- Chari: Eradication of large colon tumor xenografts by targeted delivery of maytansinoids. *Proc. Natl. Acad. Sci. USA* 93, 8618-8623 (1996).
- 5 Denis C. Roy, Sophie Ouellet, Christiane Le Houiller, Pamela D. Ariniello, Claude Perreault and John M. Lambert: Elimination of neuroblastoma and small-cell lung cancer cells with an anti-neural cell adhesion molecule immunotoxin. *J. Natl. Cancer Inst.* 88, 1136-1145 (1996).
- Walter A. Blättler, Ravi V.J. Chari and John M. Lambert: Immunoconjugates. In *Cancer Therapeutics: Experimental and Clinical Agents*. (B. Teicher, Ed.), Humana Press, Totowa, NJ, pp. 371-394 (1996).
- 10 Michael L. Grossbard, John M. Lambert, Victor S. Goldmacher, Arnold S. Freedman, Jeanne Kinsella, Danny P. Duccello, Susan N. Rabinowe, Laura Elisea, Felice Carol, James A. Taylor, Walter A. Blättler, Carol L. Epstein, and Lee M. Nadler: Anti-B4-blocked Ricin: A phase I trial of 7 day continuous infusion in patients with B-cell neoplasms. *J. Clin. Oncol.* 11, 726-737 (1993).
- 15 Michael L. Grossbard, John G. Gribben, Arnold S. Freedman, John M. Lambert, Jeanne Kinsella, Susan N. Rabinowe, Laura Eliseo, James A. Taylor, Walter A. Blättler, Carol L. Epstein, and Lee M. Nadler: Adjuvant immunotoxin therapy with anti-B4-blocked ricin following autologous bone marrow transplantation for patients with B-cell Non-Hodgkin's lymphoma.
- 20 *Blood* 81, 2263-2271 (1993).
- Sudhir A. Shah, Patricia M. Halloran, Cynthia A. Ferris, Beth A. Levine, Elizabeth A. Bourret, Victor S. Goldmacher, and Walter A. Blättler: Anti-B4-blocked Ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models. *Cancer Res.* 53, 1360-1367 (1993).
- 25 Ravi V.J. Chari, Bridget A. Martell, Jonathan L. Gross, Sherilyn B. Cook, Sudhir A. Shah, Walter A. Blättler, Sara J. McKenzie, and Victor S. Goldmacher: Immunoconjugates containing novel maytansinoids: promising anti-cancer drugs. *Cancer Res.* 52, 127-131 (1992).
- 30 John M. Lambert, Peter D. Senter, Annie Yau-Young, Walter A. Blättler, and Victor S. Goldmacher: Purified immunotoxins that are reactive with human lymphoid cells. *J. Biol. Chem.* 250, 12035-12041 (1985).

WHAT IS CLAIMED IS:

1. A process for identifying an agent that modulates the activity of a cancer-related gene comprising:
 - 5 (a) contacting a compound with a cell containing a gene that corresponds to a polynucleotide having a sequence selected from the group consisting of SEQ ID NO: 1, 2, 3 and 4 and under conditions promoting the expression of said gene; and
 - (b) detecting a difference in expression of said gene relative to when
10 said compound is not presentthereby identifying an agent that modulates the activity of a cancer-related gene.
- 2 The process of claim 1 wherein said gene has a sequence selected
15 from the group consisting of SEQ ID NO: 1, 2, 3 and 4.
3. The process of claim 1 wherein the cell is a cancer cell and the difference in expression is a decrease in expression.
- 20 4. The process of claim 3 wherein said cancer cell is a member selected from breast cancer, Wilms tumor and soft tissue fibromatosis.
5. A process for identifying an anti-neoplastic agent comprising contacting a cell exhibiting neoplastic activity with a compound first identified
25 as a cancer related gene modulator using the process of claim 1 and detecting a decrease in said neoplastic activity after said contacting compared to when said contacting does not occur.
6. The process of claim 5 wherein said neoplastic activity is
30 accelerated cellular replication.

7. The process of claim 5 wherein said decrease in neoplastic activity results from the death of the cell.

5 8. A process for identifying an anti-neoplastic agent comprising administering to an animal exhibiting a cancer condition an effective amount of an agent first identified according to the process of claim 1 and detecting a decrease in said cancerous condition.

10 9. A process for determining the cancerous status of a cell, comprising determining an increase in the level of expression in said cell of a gene that corresponds to a polynucleotide having a sequence selected from the group consisting of SEQ ID NO: 1, 2, 3 and 4 wherein an elevated expression relative to a known non-cancerous cell indicates a cancerous state or potentially cancerous state.

15

10. The process of claim 9 wherein said elevated expression is due to an increased copy number.

20 11. An isolated polypeptide comprising an amino acid sequence homologous to an amino acid sequence selected from the group consisting of SEQ ID NO: 5 and 6 wherein any difference between said amino acid sequence and the sequence of SEQ ID NO: 5 and 6 is due solely to conservative amino acid substitutions and wherein said isolated polypeptide comprises at least one immunogenic fragment.

25

12. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 5 and 6.

30 13. An antibody that reacts with a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 5 and 6.

14. The antibody of claim 13 wherein said antibody is a recombinant antibody.

5 15. The antibody of claim 13 wherein said antibody is a synthetic antibody.

16. The antibody of claim 13 wherein said antibody is a humanized antibody.

10 17. An immunoconjugate comprising the antibody of claim 13 and a cytotoxic agent.

15 18. The antibody of claim 17 wherein said cytotoxic agent is a member selected from the group consisting of a calicheamicin, a maytansinoid, an adozelesin, a cytotoxic protein, a taxol, a taxotere, a taxoid and DC1.

19. The immunoconjugate of claim 18 wherein said calicheamicin is calicheamicin γ_1^I , N-acetyl gamma calicheamicin dimethyl hydrazide or calicheamicin θ_1^I .

20

20. The immunoconjugate of claim 18 wherein said maytansinoid is DM1.

25 21. The immunoconjugate of claim 18 wherein said cytotoxic protein is ricin, abrin, gelonin, pseudomonas exotoxin or diphtheria toxin.

22. The immunoconjugate of claim 18 wherein said taxol is paclitaxel.

30 23. The immunoconjugate of claim 18 wherein said taxotere is docetaxel.

24. A process for treating cancer comprising contacting a cancerous cell *in vivo* with an agent having activity against an expression product encoded by a gene sequence selected from the group consisting of SEQ ID NO: 1, 2, 3 and 4.

5

25. The process of claim 24 wherein said agent is an antibody of claim 13.

26. The process of claim 24 wherein said agent is an immunoconjugate
10 of claim 17.

27. An immunogenic composition comprising a polypeptide of claim 11.

28. An immunogenic composition comprising a polypeptide of claim 12.
15

29. The process of claim 24 wherein said cancer is a member selected from breast cancer, Wilms tumor and soft tissue fibromatosis.

30. A process for treating cancer in an animal afflicted therewith
20 comprising administering to said animal an amount of an immunogenic composition of claim 27 sufficient to elicit the production of cytotoxic T lymphocytes specific for the polypeptide of claim 11.

31. A process for treating cancer in an animal afflicted therewith
25 comprising administering to said animal an amount of an immunogenic composition of claim 28 sufficient to elicit the production of cytotoxic T lymphocytes specific for the polypeptide of claim 12.

32. A process for treating a cancerous condition in an animal afflicted
30 therewith comprising administering to said animal a therapeutically effective amount of an agent first identified as having anti-neoplastic activity using the process of claim 8.

33. A process for protecting an animal against cancer comprising administering to an animal at risk of developing cancer a therapeutically effective amount of an agent first identified as having anti-neoplastic activity using the process of claim 8.

5

34. The process of claim 30 wherein said animal is a human being.

35. The process of claim 30 wherein said cancer is a member selected from breast cancer, Wilms tumor and soft tissue fibromatosis.

10

36. A method for producing test data with respect to the gene modulating activity of a compound comprising:

(a) contacting a compound with a cell containing a polynucleotide comprising a nucleotide sequence corresponding to a gene whose expression is increased in a cancerous cell over that in a non-cancerous cell and under conditions wherein said polynucleotide is being expressed,

15

(b) determining a change in expression of polynucleotides as a result of said contacting, and

(c) producing test data with respect to the gene modulating activity of said compound based on a decrease in the expression of the determined gene whose expression is otherwise increased in a cancerous cell over that in a non-cancerous cell indicating gene modulating activity.

20

SEQUENCE LISTING

<110> Avalon Pharmaceuticals

<120> Cancer-Linked Gene as Target for Chemotherapy

<130> 689290-159

<140>

<141>

<150> US/60/388,075

<151> 2002-06-11

<160> 6

<170> PatentIn version 3.0

<210> 1

<211> 6843

<212> DNA

<213> Homo sapiens

<400> 1

gttgacagtga	gccgagatcg	crccactgca	ctccagcctg	ggcgacrgag	cgagactttg	60
tytcaagatt	actctaaaca	gaaacaagag	tgaaataaat	ttgtggagtt	aataataaaa	120
atgttattct	ctgtggtatg	ttttcttttc	ttttgttttt	ttrrgacrgg	gtcttgctct	180
gttgcccagg	ctggagtgc	gtggcgccat	cttggtcac	tgcrccctct	gcctcccrgg	240
ttcragcgat	tctcctgcct	crggcccctg	agtrgctggg	attacaggca	cgtrccacca	300
cgccatagcta	atTTTTtatat	tttttagtaga	gacrggggtt	crccatgttg	gtcatgttgg	360
tctcgaaactc	ctgacctcat	gatctgcccc	ctgccrgcct	cccacagtgc	tgggattrca	420
ggcgtgagcc	accgcgcccc	gcctgtatTT	tttcatTTca	tagaatttcc	agataaaagt	480
cagagtcaac	tagttttata	atactgaaaa	gttttgcaaa	tacaagcatg	tcacttaatg	540
atggggatgt	gttctgagaa	atgtgtcatt	aggtgattcc	gtcattgtgc	aaatgtcata	600
gagtatactt	acataaacct	aggtgggtatg	tagcctatat	gatataatgtg	gcttatatga	660
tataccctat	tgctcctagg	ctgcaaacct	gtatagcatg	ttactatcct	gaagtcaatg	720
ggcaattgta	acacaatggc	aagtatttgt	gtattgaaac	ataagggtat	agtaaaaaata	780
tggtactatt	aatacaactg	tatgggacta	ccattgtata	tgcggtccat	cattggccaa	840
actttcttta	tggtggcaca	agactacata	ataaatggta	aagtaaccag	acttgagat	900
ggggaggagg	gagaagaatg	ccaaatgtat	gtttcctccc	acagactagc	aggcatctag	960
tatcaggcaa	cayacttata	caatcatttc	ctactcctgt	ctcacacttg	ccagaatctg	1020
gatttaattt	ttttttttta	ttgttagacc	agtaatgcag	ttttcatatt	ttgtataaca	1080
aaaaagttgt	aggacttttc	cttcttactg	tgaaaatatg	actcattaaa	tacataactt	1140
ttagtattgg	ccattttgtat	tcttatactc	ttagtcacaa	agataactac	gtttttacaaa	1200
gtcgaaaggt	taataatagc	agctagcatg	aattcagagc	ttgctatgta	ttgagcactg	1260
ggtttaaaca	catatgctct	atTTttattaa	gtccttatag	taggaaagtg	aagaatacac	1320
tagtcaactga	agttccttca	gtgctcaaga	ctcaagtgca	ctatagcaag	acaaaacacca	1380
ggaaacatgt	aactctgctt	cgaaactctt	agcaagtga	tggcccagtt	tgggaaagca	1440
agacaaacac	tggatccata	atggcttttt	acacctgatt	ggaatgcaga	aaaaatggaa	1500
ccactaacta	ctaataattat	ctttgccagc	aggtgagcag	tacatacctg	acttcagagg	1560
atTTttattga	aactcaatag	atgatgggta	ataaaaacaa	atatoctcag	ctttccttct	1620
tttacttgtc	atctgacaac	cactattttag	ctaaaactaa	aatggattag	agatacaaga	1680
tgatgaataa	caattattaa	cttttgtgag	catataatgt	gagtcagcta	ctacactaag	1740
aactttacat	agattccctt	aattttctca	ataatcctat	gagaactgtc	cttgtatgag	1800
caaccccat	ttatagctga	agatacttga	ggcttcaaga	ggttatataa	acatgttcat	1860
ggtcaacagt	tattaagcag	tgagtgcacat	tctcacgaga	ttaatgagat	catctgtgtg	1920
agatacaaat	acatctattg	tgtatgtttg	tgTTTTtaaat	ggagaccaat	ggtatgcag	1980

aatgaagtcc	ttttatcagt	cagtcaagat	ctgatgtggc	tattcaata	taggcaaaac	2040
tgatgttttc	cttttttagt	taagttaaat	gtactattta	aataactgtg	aatatttaga	2100
atattcacag	aattgtgcaa	ccatcaccac	aatcttttaga	atattttcat	catctcaaaa	2160
agatactttg	tagccttttag	cacccttccc	actgtacccc	cccccatacc	cctggccata	2220
ggcaactact	aaattacttt	ctgtccctgc	aggttgtcct	attctggata	ctttgtatat	2280
gtggaatcat	aaaataggtg	atcttttatg	actggcatct	ttcaagcatg	tttttgatat	2340
tttcatccat	gttgtaggat	attaaattaa	ctttttgcat	aggaataaact	gagctagaaa	2400
agcatgggct	gaatatgtct	gcagaatgta	gcatttagaa	aagaaagact	tccaggagac	2460
aaatgaggta	gtaactaaaa	tgtaaataac	taaaaattag	ctttgagtct	ttaataaaact	2520
acctttcatg	ttttgctttc	actaggaatg	aacttttaat	tttttgagc	tataaataca	2580
tgtagtttct	aaagacatct	ttgtttttaa	agaaaagaca	tctgcaggct	ttttcttagt	2640
gttcctatta	agtatgtatg	agtggtgca	tttgtgtgtg	tgtgtgtgca	tgttttagtga	2700
ctttacatgt	gtatacatat	aaatgtacac	agtcataat	gactagtggg	acatggaatc	2760
tcaatttaaat	tgtaaaagtg	aaggagtctt	aaaactagtt	ttagtatagt	aagtgggata	2820
tagtaagaat	gtcctacaat	ttaaaagctt	atttggttat	cttcaatgga	ttttgaatgt	2880
attcaatact	agatttgcca	gtgactatgc	cttttttagt	aacaaaagaa	aggctataat	2940
gtagaaagta	tatggaataa	gcataacatc	tgtcctaata	taattttcag	gcacatctcc	3000
agacttcaat	ttggctgaaa	taattcatgc	cacggacctg	tgcacatgcc	tggaaattgag	3060
agacacagtt	aaaagactcc	aagttgcttt	ctgccttttg	aaaactcctg	aaaaccatcc	3120
ctctggactt	tggaaattcta	cacagctcaa	ccaagacttt	gcttgaatgt	ttacattttc	3180
tgctcgctgt	cctacatatc	acaatatagt	gttcacgttt	tgttaaaact	tgggggtgtc	3240
aggagttgag	cttgctcagc	aagccagcat	ggctaggatg	agctttgtta	tagcagcttg	3300
ccaattgggtg	ctgggcctac	taatgacttc	attaaccgag	tcttccatac	agaatagtga	3360
gtgtccacaa	ctttgcgtat	gtgaaattcg	tccttggttt	acccacagct	caacttacag	3420
agaagccacc	actgttgatt	gcaatgacct	ccgcttaaca	aggattccca	gtaacctctc	3480
tagtgacaca	caagtgtctt	tcttacagag	caataacatc	gcgaagactg	tggatgagct	3540
gcagcagctt	ttcaacttga	ctgaactaga	tttctcccaa	aacaacttta	ctaaacattaa	3600
ggaggtcggg	ctggcaaac	taaccagct	cacaacgctg	catttgagg	aaaatcagat	3660
taccgagatg	actgattact	gtctacaaga	cctcagcaac	cttcaagaac	tctacatcaa	3720
ccacaaccaa	attagcacta	ttctgtctca	tgtctttgca	ggcttaaaaa	atctattaa	3780
gctccacctg	aactccaaca	aattgaaagt	tattgatagt	cgctgggttg	attctacacc	3840
caacctggaa	attctcatga	tggagaaaa	ccctgtgatt	ggaattctgg	atatgaactt	3900
caaacccttc	gcaaatttga	gaagcttagt	tttggcagga	atgtatctca	ctgatattcc	3960
tggaaatgct	ttggtgggtc	tggatagcct	tgagagcctg	tctttttatg	ataacaaact	4020
ggttaaagtc	cctcaacttg	ccctgcaaaa	agttccaaat	ttgaaattct	tagacctcaa	4080
caaaaacccc	attcacaaaa	tccaagaagg	ggacttcaaa	aatatgcttc	ggttaaaaaga	4140
actgggaatc	aacaatatgg	gcgagctcgt	ttctgtcgac	cgctatgccc	tggataactt	4200
gcctgaactc	acaaagctgg	aagccaccaa	taaccctaaa	ctctcttaca	tccaccgctt	4260
ggctttccga	agtgtccctg	ctctggaaa	cttgatgctg	aacaacaatg	ccttgaatgc	4320
catttaccaa	aagacagtcg	aatccctccc	caatctcgct	gagatcagta	tccatagcaa	4380
tccctcagg	tgtgactgtg	tgatccactg	gattaactcc	aacaaaacca	acatccgctt	4440
catggagccc	ctgtccatgt	tctgtgccat	gccgcccgaa	tataaagggc	accaggtgaa	4500
ggaagtttta	atccaggatt	cgagtgaaca	gtgcctccca	atgatatctc	acgacagctt	4560
cccaaactcg	ttaaacgtgg	atatcggcac	gacggttttc	ctagactgtc	gagccatggc	4620
tgagccagaa	cctgaaatth	actgggtcac	tcccattgga	aataagataa	ctgtggaaac	4680
cctttcagat	aaatacaagc	taagttagcga	aggtaccttg	gaaatatcta	acatacaaat	4740
tgaagactca	ggaagatata	catgtgttgc	ccagaatgtc	caaggggcag	acactcgggt	4800
ggacaacaatt	aaggttaacg	ggacccttct	ggatgggtacc	caggtgctaa	aaatatacgt	4860
caagcagaca	gaatcccatt	ccatcttagt	gtcctggaaa	gttaattcca	atgtcatgac	4920
gtcaaaactta	aaatggctcg	ctgccaccat	gaagattgat	aaccctcaca	taacatatac	4980
tgccagggtc	ccagtcgatg	tccatgaata	caacctaaag	catctgcagc	cttccacaga	5040
ttatgaagtg	tgtctcacag	tgtccaatat	tcatcagcag	actcaaaagt	catgcgtaaa	5100
tgtcacaacc	aaaaatgccg	ccttcgcagt	ggacatctct	gatcaagaaa	ccagtacagc	5160
ccttgctgca	gtaatggggt	ctatgtttgc	cgtcattagc	cttgctgcca	ttgctgtgta	5220
ctttgccaaa	agatttaaga	gaaaaaacta	ccaccactca	ttaaaaaagt	atatgcaaaa	5280
aacctcttta	atccacttaa	atgagctgta	cccaccactc	attaacctct	gggaaggtga	5340
cagcgagaaa	gacaaagatg	gttctgcaga	caccaagcca	acccaggtcg	acacatccag	5400
aagctattac	atgtggtaac	tcagaggata	ttttgcttct	ggtagtaagg	agcacaagaa	5460
cgtttttgct	ttattctgca	aaagtgaaca	agttgaagac	ttttgtattt	ttgactttgc	5520

tagtttgtgg	cagagtggag	aggacgggtg	gatatttcaa	atTTTTTTtag	tatagcgtat	5580
cgcaagggtt	tgacacggct	gccagcgact	ctaggcttcc	agtctgtgtt	tggtttttat	5640
tcttatcatt	attatgattg	ttattatatt	attattttat	tttagttgtt	gtgctaaact	5700
caataatgct	gttctaacta	cagtgtctca	taaaatgatt	aatgacagga	tgggggtccc	5760
ctgtgctttt	accagtagca	tgacccttcc	tgaagccatc	cgtagaaagt	actttgtcct	5820
ccaaaaagct	aacatacggt	tttgaagcag	cattgaaact	tttgtagcaa	tctgggtctat	5880
agacttttaa	ctcaagaagc	taaggctaga	cttgttacct	tcgttgaatg	atggttagttg	5940
actgtactgt	aatgttgtat	caactgaatt	gaatgtttgc	ctttaaacia	tgaattttct	6000
ttttctttcc	tttttttttt	tttgttgtaa	tagttaaaga	ggcttagaac	aagctaacag	6060
gcaatagaaa	tatgtatatc	agatttttta	atgtaacaaa	ctacatgtta	attgttatct	6120
tattcttttt	atcttttagta	gacactttta	aaagaaaaga	caattttgtt	gtgtttaact	6180
caccaacacg	tgggtgtataa	tgaagacaga	actataataa	attagttttg	ttctgatttt	6240
ttagaacact	tgcaataatg	tatcatttat	agttcttgc	agttgcagt	gtaatatattt	6300
tcacatccat	aaaaacaact	accaaataa	atcagctgta	gcatgttgc	ttttaaagct	6360
aggccctaaa	aggtttta	tctttttcta	aggaagaaa	tgtctatttt	aattaagata	6420
ttttaatgaa	caggatttct	gtatttttaa	tagtactgac	tagcacctaa	tgggcagtgg	6480
gagggtgggt	catatgaaga	aaaaaaaggt	gtattgttgt	atcccatgca	taaataaagg	6540
taaatatata	tatacaccaa	tatatccata	tatactcaca	cacatcccaa	cctgtcacac	6600
acaatgcgtg	tgtatatata	tatgaatata	ttggatatgt	catttctgta	agagttttgt	6660
taaaacctga	ttttcttttg	tagtatccac	attcttcatc	aaagtacaaa	aacgtctgtg	6720
gagtgtcaca	aactgtatga	catgttattt	ctttttaaca	gttgtctata	tgcttagacc	6780
cgtgttagtc	tctatatctg	tgtggcaata	tctgctgaga	caagtaaagt	attaatagaa	6840
aac						6843

<210> 2
 <211> 6243
 <212> DNA
 <213> Homo sapiens

<400>	2					
gttgacgtga	gccgagatcg	crccactgca	ctccagcctg	ggcgacrgag	cgagactttg	60
tytcaagatt	actctaaaca	gaaacaagag	tgaaataaat	ttgtggagtt	aataataaaa	120
atgttattct	ctgtgggtatg	ttttcttttc	ttttgttttt	ttrrgacrgg	gtcttgctct	180
gttgcccagg	ctggagtgc	gtggcgccat	cttggtcac	tgrrrctct	gcctcccrgg	240
ttcragcgat	tctcctgcct	crggccctg	agtrgctggg	attacaggca	cgtreccacca	300
cgcctagcta	atTTTTatat	tttttagtaga	gacrgggttt	crccatgttg	gtcatgttgg	360
tctcgaactc	ctgacctcat	gatctgcccc	ctgccrgcct	cccacagtgc	tgggatttca	420
ggcgtgagcc	accgcgccg	gacctgtattt	tttcatttca	tagaatttcc	agataaaaagt	480
cagagtcaac	tatgtttata	atactgaaaa	gttttgcaaa	tacaagcatg	tactttaatg	540
atggggatgt	gttctgagaa	atgtgtcatt	aggtgattcc	gtcattgtgc	aaatgtcata	600
gagtatactt	acataaacct	aggtggtatg	tagcctatat	gatataatgtg	gcttatatga	660
tataccctat	tgctcctagg	ctgcaaacct	gtatagcatg	ttactatcct	gaagtcaatg	720
ggcaattgta	acacaatggc	aagtatttgt	gtattgaaac	ataagggtat	agtaaaaaata	780
tggtactatt	aatacaactg	tatgggacta	ccattgtata	tgcgggtccat	cattggccaa	840
actttcttta	tgggtggcaca	agactacata	ataaatggta	aaagtaaccag	acttggagat	900
ggggaggagg	gagaagaatg	ccaaatgtat	gtttcctccc	acagactagc	aggcatctag	960
tatcaggcaa	cayacttata	caatcatttc	ctactcctgt	ctcacacttg	ccagaatctg	1020
gatttaattt	ttttttttta	ttgttagacc	agtaatgcag	ttttcataatt	ttgtataaca	1080
aaaaagttgt	aggacttttc	cttcttactg	tgaaaatatg	actcattaaa	tacataactt	1140
ttagtattgg	ccatttgtat	tcttatactc	ttagtcacaa	agataactac	gttttacaaa	1200
gtcgaaaggt	taataatagc	agctagcatg	aattcagagc	ttgctatgta	ttgagcactg	1260
ggttttaaca	catatgctct	attttattaa	gtccttatag	taggaaagtg	aagaatacac	1320
tagtcaactga	agttccttca	gtgctcaaga	ctcaagtgca	ctatagcaag	acaaacacca	1380
ggaaacatgt	aactctgctt	cgaatacttt	agcaagtga	tggcccagtt	tgggaaagca	1440
agacaaaacac	tggatccata	atggcttttt	acacctgatt	ggaatgcaga	aaaaatggaa	1500
ccactaacta	ctaataattat	ctttgccagc	aggtgagcag	tacataacctg	acttcagagg	1560
atTTTattga	aactcaatag	atgatggtta	ataaaaaaca	atatcctcag	ctttccttct	1620
tttacttgtc	atctgacaac	cactatttag	ctaaaactaa	aatggattag	agatacaaga	1680

tgatgaataa	caattatttaa	ottttgtgag	catataatgt	gagtcagcta	ctacactaag	1740
aactttacat	agattccctt	aattttctca	ataatcctat	gagaactgtc	cttgtatgag	1800
caaccccatt	ttatagctga	agatacttga	ggcttcaaga	ggttatataa	acatgttcat	1860
ggtcaacagt	tattaaagcag	tgagtgcacat	tctcacgaga	ttaatgagat	catctgtgtg	1920
agatacaaat	acatctattg	tgtatgtttg	tgtttttaat	ggagaccaat	ggtatgacag	1980
aatgaagtcc	ttttatcagt	cagtcaagat	ctgatgtggc	tattcaaata	taggcaaaac	2040
tgatgttttc	cttttttagt	taagttaaat	gtactattta	aataactgtg	aatattttaga	2100
atattcacag	aattgtgcaa	ccatcaccac	aatctttaga	atattttcat	catctcaaaa	2160
agatactttg	tagccttttag	cacccttccc	actgtacccc	cccccatacc	cctggccata	2220
ggcaactact	aaattacttt	ctgtccctgc	aggttgtcct	attctggata	ctttgtatat	2280
gtggaatcat	aaaataggtg	atctttttatg	actggcatct	ttcaagcatg	tttttgatat	2340
tttcatccat	gttgtaggat	attaaattaa	ctttttgcac	aggaataact	gagcatagaaa	2400
agcatgggct	gaatatgtct	gcagaatgta	gcatttagaa	aagaaagact	tccaggagac	2460
aaatgaggta	gtaactaaaa	tgtaaataac	taaaaattag	ctttgagtct	tttaataaact	2520
acctttcatg	ttttgctttc	actaggaatg	aacttttaat	tttttggagc	tataaataca	2580
tgtagtttct	aaagacatct	ttgttttttaa	agaaaagaca	tctgcaggct	ttttcttagt	2640
gttcctatta	agtatgtatg	agtgtgtgca	tttgtgtgtg	tgtgtgtgca	tgttttagtga	2700
ctttacatgt	gtatacatatc	aaatgtacac	agtcatatat	gactagtggg	acatggaatc	2760
tcaatttaat	tgtaaaagtg	aaggagtctt	aaaactagtt	ttagtatagt	aagtgggata	2820
tagtaagaat	gtcctacaat	ttaaaagcct	atttggttat	cttcaatgga	ttttgaatgt	2880
attcaatact	agatttgoga	gtgactatgc	cttttttagta	aacaaaagaa	aggctataat	2940
gtagaagaat	tatggaataa	gcataaacatc	tgtcctaatac	taattttcag	gcacatctcc	3000
agacttcaat	ttggctgaaa	taattcatgc	cacggacctg	tgcacatgcc	tgggaattgag	3060
agacacagtt	aaaagactcc	aagttgcttt	ctgccttttg	aaaactcctg	aaaaccatcc	3120
ctctggactc	tgggaattcta	cacagctcaa	ccaagacttt	gcttgaatgt	ttacattttc	3180
tgctcgctgt	cctacatatc	acaatatagt	gttcacgttt	tgttaaaact	ttggggtgtc	3240
aggagttgag	cttgctcagc	aagccagcat	ggctaggatg	agctttgtta	tagcagcttg	3300
ccaattgggtg	ctgggcctac	taatgacttc	attaaccgag	tcttccatac	agaatagtga	3360
gtgtccacaa	ctttgcgtat	gtgaaattcg	tccctggttt	acccacacag	caacttacag	3420
agaagccacc	actggtgatt	gcaatgacct	ccgcttaaca	aggattccca	gtaacctctc	3480
tagtgacaca	caagtgcctc	tcttacagag	caataacatc	gcgaagactg	tggatgagct	3540
gcagcagctt	ttcaacttga	ctgaactaga	tttctcccaa	aacaacttta	ctaactataa	3600
ggagggtcggg	ctggcacaacc	taaccacagct	cacaacgctg	catttggagg	aaaatcagat	3660
taccgagatg	actgattact	gtctacaaga	cctcagcaac	cttcaagaac	tctacatcaa	3720
ccacaaccaa	attagcacta	tttctgctca	tgtttttgca	ggcttaaaaa	atctatttaag	3780
gtccacactg	aactccaaca	aattgaaagt	tattgatagt	cgctgggttg	attctacacc	3840
caacctggaa	attctcatga	tgggagaaaa	ccctgtgatt	ggaattctgg	atatgaactt	3900
caaacccctc	gcaaatttga	gaagcttagt	tttggcagga	atgtatctca	ctgatatccc	3960
tggaaatgct	ttgttgggtc	tggatagcct	tgagagcctg	tcttttttatg	atacaaaact	4020
ggttaaagtc	cctcaacttg	ccctgcaaaa	agttccaaat	ttgaaattct	tagacctcaa	4080
caaaaacccc	attcacaaaa	tccaagaagg	ggacttcaaa	aatatgcttc	ggttaaaaga	4140
actgggaatc	aacaatatgg	gcgagctcgt	ttctgtcgac	cgctatgccc	tggataactt	4200
gcctgaactc	acaaagctgg	aagccaccaa	taaccctaaa	ctctcttaca	tccaccgctt	4260
ggctttccga	agtgtccctg	ctctggaaag	cttgatgctg	aacaacaatg	ccttgaatgc	4320
catttaccaa	aagacagtgc	aatccctccc	caatctgogt	gagatcagta	tccatagcaa	4380
tcccctcagg	tgtgactgtg	tgatccactg	gattaactcc	aacaaaacca	acatccgctt	4440
catggagccc	ctgtccatgt	tctgtgccat	gcgcgccgaa	tataaagggc	accaggtgaa	4500
ggaagtttta	atccaggatt	cgagtgaaca	gtgcctccca	atgatatctc	acgacagctt	4560
cccaaactgt	ttaaacgtgg	atatcggcac	gacggttttc	ctagactgtc	gagccatggc	4620
tgagccagaa	cctgaaattt	actgggtcac	tcccattgga	aataagataa	ctgtggaaac	4680
cctttcagat	aaatacaagc	taagtagcga	aggtaccttg	gaaatatcta	acatacaaat	4740
tgaagactca	ggaagatata	catgtgttgc	ccagaatgtc	caaggggcag	acactcgggt	4800
ggcaacaatt	aaggttaacg	ggacccttct	ggatgggtacc	caggtgctaa	aaatatacgt	4860
caagcagaca	gaatcccatt	ccatcttagt	gtcctggaaa	gttaattcca	atgtcatgac	4920
gtcaaaactta	aaatggctgt	ctgccaccat	gaagattgat	aaccctcaca	taacatatac	4980
tgccagggtc	ccagtcgatg	tccatgaata	caacctaacg	catctgcagc	cttccacaga	5040
ttatgaagtg	tgtctcacag	tgtccaatat	tcatacagag	actcaaaaagt	catgcgtaaa	5100
tgtcaaaccc	aaaaatgccg	ccttcgcagt	ggacatctct	gatcaagaaa	ccagtcacagc	5160
cctcgctgca	gtaatggggg	ctatgtttgc	cgctcattagc	cttgcgtcca	ttgctgtgta	5220

ctttgccaaa	agatttaaga	gaaaaaacta	ccaccactca	ttaaaaaagt	atatgcaaaa	5280
aacctcttca	atcccactaa	atgagctgta	cccaccactc	attaacctct	gggaagggtga	5340
cagcgagaaa	gacaaagatg	gttctgcaga	caccaagcca	accaggtcg	acacatccag	5400
aagctattac	atgtggtaac	tcagaggata	ttttgcttct	ggtagtaagg	agcacaaaaga	5460
cgtttttgct	ttattctgca	aaagtgaaca	agttgaagac	ttttgtattt	ttgactttgc	5520
tagtttggtg	cagagtggag	aggacgggtg	gatatttcaa	atTTTTTTtag	tatagcgtat	5580
cgcaagggtt	tgacacggct	gccagcgact	ctaggcttcc	agtctgtgtt	tggtttttat	5640
tcttatcatt	attatgattg	ttattatatt	attattttat	tttagttgtt	gtgctaaact	5700
caataatgct	gttctaacta	cagtgtctca	taaaatgatt	aatgacagga	tgggggttccc	5760
ctgtgctttt	accagtagca	tgaccccttc	tgaagccatc	cgtagaaagt	actttgtcct	5820
ccaaaaagct	aacatacggg	tttgaagcag	cattgaaact	ttttagcaaa	tctgggtctat	5880
agacttttaa	ctcaagaagc	taaggctaga	cttgttacct	tcgttgaatg	atgttagttg	5940
actgtactgt	aatgttgtat	caactgaatt	gaatgtttgc	ctttaaacia	tgaattttct	6000
ttttctttcc	tttttttttt	tttgttgtaa	tagttaaaga	ggcttagaac	aagctaacag	6060
gcaatagaaa	tatgtatatc	agatttttta	atgtaacaaa	ctacatgtta	attgttatct	6120
tattcttttt	atcttttagta	gacactttta	aaagaaaaga	caattttgtt	gtgtttaact	6180
caccaacacg	tggtgtataa	tgaagacaga	actataataa	attagttttg	ttctgatttt	6240
tta						6243

<210> 3

<211> 3912

<212> DNA

<213> Homo sapiens

<400> 3

cgccgccgtg	ggtgccgggt	ccgcgcgcac	cccaacaccc	ccaccagctg	ggcctcgggg	60
cacatctcca	gacttcaatt	tggtgaaat	aattcatgcc	acggacctgt	gcacatgcct	120
ggaattgaga	gacacagtta	aaagactcca	agttgctttc	tgctttttga	aaactcctga	180
aaaccatccc	tctggactct	ggaattctac	acagctcaac	caagactttg	cttgaatgtt	240
tacattttct	gctcgctgtc	ctacatatca	caatatagtg	ttcacgtttt	gttaaaactt	300
tgggggtgtca	ggagttgagc	ttgctcagca	agccagcatg	gctaggatga	gctttgttat	360
agcagcttgc	caattgggtg	tgggcctact	aatgacttca	ttaaccgagt	cttccataca	420
gaatagttag	tgtccacaac	tttgcgtatg	tgaattcgt	ccctgggtta	ccccacagtc	480
aacttacaga	gaagccacca	ctgttgattg	caatgacctc	cgcttaacaa	ggattcccag	540
taacctctct	agtgcacac	aaagtgttct	cttacagagc	aataacatcg	cgaagactgt	600
ggatgagctg	cagcagcttt	tcaacttgac	tgaactagat	ttctcccaaa	acaactttac	660
taacattaag	gaggtcgggc	tggcaaacct	aaccagctc	acaacgctgc	atttggagga	720
aaatcagatt	accgagatga	ctgattactg	tctacaagac	ctcagcaacc	ttcaagaact	780
ctacatcaac	cacaaccaaa	ttagcactat	ttctgctcat	gcttttgagc	gttataaaaa	840
tctattaagg	ctccacctga	actccaacaa	attgaaagtt	attgatagtc	gctgggttga	900
ttctacaccc	aacctggaaa	ttctcatgat	cggagaaaac	cctgtgattg	gaattctgga	960
tatgaacttc	aaaccctcgc	caaatttgag	aagcttagtt	ttggcaggaa	tgtatctcac	1020
tgatattcct	ggaaatgctt	tggtgggtct	ggatagcctt	gagagcctgt	ctttttatga	1080
taacaaactg	gttaaagtcc	ctcaacttgc	cctgcaaaaa	gttccaaatt	tgaatttctt	1140
agacctcaac	aaaaacccca	ttcacaataa	ccaagaaggg	gacttcaaaa	atatgcttcg	1200
gttaaaagaa	ctgggaatca	acaatatggg	cgagctcggt	tctgtcgacc	gctatgccct	1260
ggataacttg	cctgaactca	caaagctgga	agccaccaat	aaccctaaac	tctcttacat	1320
ccaccgcttg	gctttccgaa	gtgtccctgc	tctggaaagc	ttgatgctga	acaacaatgc	1380
cttgaatgcc	atttaccaaa	agacagtcga	atccctcccc	aatctgcgtg	agatcagtat	1440
ccatagcaat	ccctcaggt	gtgactgtgt	gatccactgg	attaactcca	acaaaaccaa	1500
catccgcttc	atggagcccc	tgtccatgtt	ctgtgccatg	ccgcccgaat	ataaagggca	1560
ccaggtgaag	gaagttttta	tccaggattc	gagtgaacag	tgctcccaa	tgatatctca	1620
cgacagcttc	ccaaatcggt	taaacgtgga	tatcggcacg	acggttttcc	tagactgtcg	1680
agccatggct	gagccagaac	ctgaaattta	ctgggtcact	cccattggaa	ataagataac	1740
tgtggaaacc	ctttcagata	aatacaagct	aagtagcgaa	ggtaccttgg	aaatatctaa	1800
catacaaaat	gaagactcag	gaagatacac	atgtgttgcc	cagaatgtcc	aaggggcaga	1860
cactcgggtg	gcaacaatta	aggttaacgg	gaccttctg	gatggtagcc	aggtgctaaa	1920
aatatacgtc	aagcagacag	aatcccatte	catcttagtg	tcctggaaag	ttaattccaa	1980

tgatcatgacg	tcaaacttaa	aatgggtcgtc	tgccaccatg	aagattgata	accctcacat	2040
aacatatact	gccagggtcc	cagtcgatgt	ccatgaatac	aacctaacgc	atctgcagcc	2100
ttccacagat	tatgaagtgt	gtctcacagt	gtccaatatt	catcagcaga	ctcaaaagtc	2160
atgctgtaaat	gtcacaca	aaaatgccgc	cttgcagtg	gacatctctg	atcaagaaac	2220
cagtacagcc	cttgctgcag	taatgggggtc	tatgtttgcc	gtcattagcc	ttgcgtccat	2280
tgctgtgtac	tttgccaaaa	gatttaagag	aaaaaactac	caccactcat	taaaaaagta	2340
tatgcaaaaa	acctcttcaa	tcccactaaa	tgagctgtac	ccaccactca	ttaacctctg	2400
ggaaggtgac	agcgagaaag	acaagatgg	ttctgcagac	accaagccaa	cccaggtcga	2460
cacatccaga	agctattaca	tgtggtaact	cagaggatat	tttgcttctg	gtagtaagga	2520
gcacaaagac	gtttttgctt	tattctgcaa	aagtgaacaa	gttgaagact	tttgtatttt	2580
tgactttgct	agtttggtgc	agagtggaga	ggacgggtgg	atatttcaaa	tttttttagt	2640
atagcgtatc	gcaagggttt	gacacggctg	ccagcgactc	taggcttcca	gtctgtgttt	2700
ggttttttatt	cttatcatta	ttatgattgt	tattatatta	ttattttatt	ttagtgtgtg	2760
tgctaaactc	aataatgctg	ttctaactac	agtgtcfaat	aaaatgatta	atgacaggat	2820
gggggttcccc	tgtgctttta	ccagtagcat	gaccttctct	gaagccatcc	gtagaaagta	2880
ctttgtcctc	caaaaagcta	acatacgggt	ttgaagcagc	attgaaactt	ttgtagcaat	2940
ctgggtctata	gacttttaac	tcaagaagct	aaggctagac	ttgttacctt	cgttgaatga	3000
tgtttagttga	ctgtactgta	atgttgtatc	aactgaattg	aatgtttgcc	tttaaacaaat	3060
gaattttctt	tttctttcct	tttttttttt	ttgttgtaat	agttaaagag	gcttagaaca	3120
agctaacagg	caatagaaat	atgtatatca	gatttttttaa	tgtaacaaac	tacatgttaa	3180
ttgtttatctt	attcttttta	tctttagtag	acacttttaa	aagaaaagac	aattttgttg	3240
tgtttaactc	accaacacgt	ggtgtataat	gaagacagaa	ctataataaa	ttagttttgt	3300
tctgattttt	tagaacactt	gcaataatgt	atcatttata	gttcttgcta	gttgacgtgg	3360
taatatTTTT	cacatccata	aaaacaacta	ccaaaataaa	tcagctgtag	catgttgctt	3420
tttaaaagcta	ggccctaaaa	ggttttaatt	ctttttctaa	gggaagaaat	gtctatttta	3480
attaagatat	tttaatgaac	aggatttctg	tatttttaaat	agtactgact	agcacctaata	3540
gggcagtgagg	aggggtggtc	atatgaagaa	aaaaaagggtg	tattgtttgta	tcccatgcat	3600
aaataaagggt	aaatatatat	atacaccaat	atattcatat	atactcacac	acatcccaac	3660
ctgtcacaca	caatgcgtgt	gtatatatat	atgaatatat	tggtatgtgc	attctgttaa	3720
gagtttttgt	aaaacctgat	tttcttttgt	agtatccaca	ttcttcatca	aagtacaaaa	3780
acgtctgtgg	agtgtcacaa	actgtatgac	atgttatttc	tttttaacag	ttgtctatat	3840
gcttagaccc	gtgttagtct	ctatatctgt	gtggcaatat	ctgctgagac	aagtaaatga	3900
ttaatagaaa	ac					3912

<210> 4
 <211> 4173
 <212> DNA
 <213> Homo sapiens

<400> 4						
gcggcgccgcg	actcggcgct	tccccgcgcg	ccgcccagg	agtccttgcc	tggcaagctg	60
gggctcgggg	aaaagtccag	cagcgagagg	gcgcggtgtc	ccgggacggt	tccaggggag	120
cccgcgcgga	aacgcggacc	aggcgcttcg	gcccggatgc	cggatccagg	agaaggggac	180
ctcgcttgcc	gtgtccaccg	ccgcggcccc	ggcgccaaga	acagagcctg	gccgtgagtg	240
aacgactggc	cgggggtacaa	atggttctga	agcacttgaa	gctcacaggc	aaaggctaag	300
agtctaaatc	ccatcccgcg	gcacatctcc	agacttcaat	ttggctgaaa	taattcatgc	360
cacggacctg	tgcacatgcc	tggaattgag	agacacagtt	aaaagactcc	aagttgcttt	420
ctgccttttg	aaaactcctg	aaaaccatcc	ctctggactc	tggaattcta	cacagctcaa	480
ccaagacttt	gcttgaatgt	ttacattttc	tgctcgctgt	cctacatatc	acaatatagt	540
gttcacgttt	tgttaaaact	ttgggggtgc	aggagttgag	cttgctcagc	aagccagcat	600
ggctaggatg	agctttgtta	tagcagcttg	ccaattgggtg	ctgggcctac	taatgacttc	660
attaaccgag	tcttccatac	agaatagtg	gtgtccacaa	ctttgcgtat	gtgaaattcg	720
tccctggttt	acccacacag	caacttacag	agaagccacc	actgttgatt	gcaatgacct	780
ccgcttaaca	aggattccca	gtaacctctc	tagtgacaca	caagtgtctc	ctttacagag	840
caataacatc	gcgaagactg	tggtatgagc	gcagcagctt	ttcaacttga	cttgaactaga	900
ttttctccaa	aacaacttta	ctaaccattaa	ggaggtcggg	ctggcaaacc	taaccacagct	960
cacaacgctg	catttgagg	aaaatcagat	taccgagatg	actgattact	gtctacaaga	1020
cctcagcaac	cttcaagaac	tctacatcaa	ccacaaccaa	attagcacta	tttctgctca	1080

tgctttttgca	ggcttaaaaa	atctattaag	gctccacctg	aactccaaca	aattgaaagt	1140
tattgatagt	cgctggtttg	attctacacc	caacctggaa	attctcatga	tcggagaaaa	1200
ccctgtgatt	ggaattctgg	atatgaactt	caaacccttc	gcaaatttga	gaagcttagt	1260
tttggcagga	atgtatctca	ctgatatctc	tggaaatgct	ttgggtgggtc	tggatagcct	1320
tgagagcctg	tctttttatg	ataacaaact	ggttaaagtc	cctcaacttg	ccctgcaaaa	1380
agttccaaat	ttgaaattct	tagacctcaa	caaaaacccc	attcacaaaa	tccaagaagg	1440
ggacttcaaa	aatatgcttc	ggttaaaaga	actgggaatc	aacaatatgg	gcgagctcgt	1500
ttctgtcgac	cgctatgccc	tggataactt	gcctgaactc	acaaagctgg	aagccaccaa	1560
taaccctaaa	ctctcttaca	tccaccgctt	ggctttccga	agtggtccctg	ctctggaaaag	1620
cttgatgctg	aacaacaatg	ccttgaatgc	catttaccaa	aagacagtcg	aatccctccc	1680
caatctgcgt	gagatcagta	tccatagcaa	tccctcagg	tgtgactgtg	tgatccactg	1740
gattaactcc	aacaaaacca	acatccgctt	catggagccc	ctgtccatgt	tctgtgccat	1800
gccgcccgaa	tataaagggc	accaggtgaa	ggaagtttta	atccaggatt	cgagtgaaca	1860
gtgcctccca	atgatattct	acgacagctt	cccaaactgt	ttaaacgtgg	atatacggcac	1920
gacgggtttc	ctagactgtc	gagccatggc	tgagccagaa	cctgaaattt	actgggtcac	1980
tcccattgga	aataagataa	ctgtggaaac	cctttcagat	aaatacaagc	taagtagcga	2040
aggtaccttg	gaaatatcta	acatacaaat	tgaagactca	ggaagatata	catgtgttgc	2100
ccagaatgtc	caaggggagc	acactcgggt	ggcaacaatt	aagggttaacg	ggacccttct	2160
ggatggtacc	caggtgctaa	aaatatacgt	caagcagaca	gaatcccatt	ccatcttagt	2220
gtcctggaaa	gttaattcca	atgtcatgac	gtcaaactta	aatgggtcgt	ctgccaccat	2280
gaagattgat	aaccctcaca	taacatatac	tgccagggtc	ccagtcgatg	tgacacgaata	2340
caacctaacg	catctgcagc	cttccacaga	ttatgaagtg	tgtctcacag	tgtccaatat	2400
tcatcagcag	actcaaaagt	catgcgtaaa	tgtcacaacc	aaaaatgccg	ccttcgcagt	2460
ggacatctct	gatcaagaaa	ccagtacagc	ccttgctgca	gtaatggggt	ctatgtttgc	2520
cgctattagc	cttgctgcca	ttgctgtgta	ctttgccaaa	agatttaaga	gaaaaaacta	2580
ccaccactca	ttaaaaaagt	atatgcaaaa	aacctcttca	atcccactaa	atgagctgta	2640
cccaccactc	attaacctct	gggaagggtga	cagcgagaaa	gacaaagatg	gttctgcaga	2700
caccaagcca	accaggtcgt	acacatccag	aagctattac	atgtggtaac	tcagaggata	2760
ttttgcttct	ggtagtaagg	agcacaaaga	cgtttttctg	ttattctgca	aaagtgaaca	2820
agttgaagac	ttttgtattt	ttgactttgc	tagtttctgg	cagagtggag	aggacgggtg	2880
gatattttcaa	attttttttag	tatagcgtat	cgcaagggtt	tgacacggct	gccagcgact	2940
ctaggcttcc	agtctgtgtt	tggtttttat	tcttatcatt	attatgattg	ttattatatt	3000
attatttttat	tttagttgtt	gtgctaaact	caataatgct	gttctaacta	cagtgtctca	3060
taaaatgatt	aatgacagga	tggggttccc	ctgtgctttt	accagtagca	tgaccccttc	3120
tgaagccatc	cgtagaaaagt	actttgtcct	ccaaaaagct	aacatacggg	tttgaagcag	3180
cattgaaact	tttgtagcaa	tctgggtctat	agacttttaa	ctcaagaagc	taaggctaga	3240
cttggttacct	tcgttgaatg	atgttagttg	actgtactgt	aatgttgtat	caactgaatt	3300
gaatgtttgc	ctttaaacia	tgaattttct	ttttctttcc	tttttttttt	tttgttgtaa	3360
tagttaaaga	ggcttagaac	aagctaacag	gcaatagaaa	tatgtatatc	agatttttta	3420
atgtaacaaa	ctacatgtta	attgttatct	tattcttttt	atcttttagta	gacactttta	3480
aaagaaaaga	caatttttgtt	gtgttttaact	caccaacacg	tgggtgtataa	tgaagacaga	3540
actataataa	attagttttg	ttctgatttt	ttagaacact	tgcaataatg	tatcatttat	3600
agttcttgct	agttgcagtg	gtaatatattt	tcacatccat	aaaaacaact	acaaaaataa	3660
atcagctgta	gcatgttgct	ttttaaagct	aggccctaaa	aggttttaat	tctttttcta	3720
agggaagaaa	tgtctatattt	aattaagata	ttttaatgaa	caggattttct	gtatttttaa	3780
tagtactgac	tagcacctaa	tgggcagtggt	gaggggtggt	catatgaaga	aaaaaaaagg	3840
gtattgttgt	atcccatgca	taaataaagg	taaatatata	tatacaccaa	tatatccata	3900
tatactcaca	cacatcccaa	cctgtcacac	acaatgcgtg	tgtatatata	tatgaatata	3960
ttggatatgt	catttctgta	agagttttgt	taaaacctga	ttttcttttg	tagtatccac	4020
attcttcac	aaagtacaaa	aacgtctgtg	gagtgtcaca	aactgtatga	catgttatatt	4080
ctttttaaca	gttgtctata	tgcttagacc	cgtgttagtc	tctatatctg	tgtggcaata	4140
tctgtctgaga	caagtaaatg	attaatagaa	aac			4173

<210> 5
 <211> 812
 <212> PRT
 <213> Homo sapiens
 <400> 5

Met Phe Gln Ala His Leu Gln Thr Phe Asn Leu Ala Glu Ile Ile His
 1 5 10 15
 Ala Thr Asp Leu Cys Thr Cys Leu Glu Leu Arg Asp Thr Val Lys Arg
 20 25 30
 Leu Gln Val Ala Phe Cys Leu Leu Lys Thr Pro Glu Asn His Pro Ser
 35 40 45
 Gly Leu Trp Asn Ser Thr Gln Leu Asn Gln Asp Phe Ala Val Asn Val
 50 55 60
 Tyr Ile Phe Cys Ser Leu Ser Tyr Ile Ser Gln Tyr Ser Val His Val
 65 70 75 80
 Leu Leu Lys Leu Trp Gly Val Arg Ser Glu Leu Ala Gln Gln Ala Ser
 85 90 95
 Met Ala Arg Met Ser Phe Val Ile Ala Ala Cys Gln Leu Val Leu Gly
 100 105 110
 Leu Leu Met Thr Ser Leu Thr Glu Ser Ser Ile Gln Asn Ser Glu Cys
 115 120 125
 Pro Gln Leu Cys Val Cys Glu Ile Arg Pro Trp Phe Thr Pro Gln Ser
 130 135 140
 Thr Tyr Arg Glu Ala Thr Thr Val Asp Cys Asn Asp Leu Arg Leu Thr
 145 150 155 160
 Arg Ile Pro Ser Asn Leu Ser Ser Asp Thr Gln Val Leu Leu Leu Gln
 165 170 175
 Ser Asn Asn Ile Ala Lys Thr Val Asp Glu Leu Gln Gln Leu Phe Asn
 180 185 190
 Leu Thr Glu Leu Asp Phe Ser Gln Asn Asn Phe Thr Asn Ile Lys Glu
 195 200 205
 Val Gly Leu Ala Asn Leu Thr Gln Leu Thr Thr Leu His Leu Glu Glu
 210 215 220
 Asn Gln Ile Thr Glu Met Thr Asp Tyr Cys Leu Gln Asp Leu Ser Asn
 225 230 235 240
 Leu Gln Glu Leu Tyr Ile Asn His Asn Gln Ile Ser Thr Ile Ser Ala
 245 250 255
 His Ala Phe Ala Gly Leu Lys Asn Leu Leu Arg Leu His Leu Asn Ser
 260 265 270
 Asn Lys Leu Lys Val Ile Asp Ser Arg Trp Phe Asp Ser Thr Pro Asn
 275 280 285
 Leu Glu Ile Leu Met Ile Gly Glu Asn Pro Val Ile Gly Ile Leu Asp
 290 295 300
 Met Asn Phe Lys Pro Leu Ala Asn Leu Arg Ser Leu Val Leu Ala Gly
 305 310 315 320

Met Tyr Leu Thr Asp Ile Pro Gly Asn Ala Leu Val Gly Leu Asp Ser
 325 330 335
 Leu Glu Ser Leu Ser Phe Tyr Asp Asn Lys Leu Val Lys Val Pro Gln
 340 345 350
 Leu Ala Leu Gln Lys Val Pro Asn Leu Lys Phe Leu Asp Leu Asn Lys
 355 360 365
 Asn Pro Ile His Lys Ile Gln Glu Gly Asp Phe Lys Asn Met Leu Arg
 370 375 380
 Leu Lys Glu Leu Gly Ile Asn Asn Met Gly Glu Leu Val Ser Val Asp
 385 390 395 400
 Arg Tyr Ala Leu Asp Asn Leu Pro Glu Leu Thr Lys Leu Glu Ala Thr
 405 410 415
 Asn Asn Pro Lys Leu Ser Tyr Ile His Arg Leu Ala Phe Arg Ser Val
 420 425 430
 Pro Ala Leu Glu Ser Leu Met Leu Asn Asn Asn Ala Leu Asn Ala Ile
 435 440 445
 Tyr Gln Lys Thr Val Glu Ser Leu Pro Asn Leu Arg Glu Ile Ser Ile
 450 455 460
 His Ser Asn Pro Leu Arg Cys Asp Cys Val Ile His Trp Ile Asn Ser
 465 470 475 480
 Asn Lys Thr Asn Ile Arg Phe Met Glu Pro Leu Ser Met Phe Cys Ala
 485 490 495
 Met Pro Pro Glu Tyr Lys Gly His Gln Val Lys Glu Val Leu Ile Gln
 500 505 510
 Asp Ser Ser Glu Gln Cys Leu Pro Met Ile Ser His Asp Ser Phe Pro
 515 520 525
 Asn Arg Leu Asn Val Asp Ile Gly Thr Thr Val Phe Leu Asp Cys Arg
 530 535 540
 Ala Met Ala Glu Pro Glu Pro Glu Ile Tyr Trp Val Thr Pro Ile Gly
 545 550 555 560
 Asn Lys Ile Thr Val Glu Thr Leu Ser Asp Lys Tyr Lys Leu Ser Ser
 565 570 575
 Glu Gly Thr Leu Glu Ile Ser Asn Ile Gln Ile Glu Asp Ser Gly Arg
 580 585 590
 Tyr Thr Cys Val Ala Gln Asn Val Gln Gly Ala Asp Thr Arg Val Ala
 595 600 605
 Thr Ile Lys Val Asn Gly Thr Leu Leu Asp Gly Thr Gln Val Leu Lys
 610 615 620
 Ile Tyr Val Lys Gln Thr Glu Ser His Ser Ile Leu Val Ser Trp Lys

625 630 635 640
 Val Asn Ser Asn Val Met Thr Ser Asn Leu Lys Trp Ser Ser Ala Thr
 645 650 655
 Met Lys Ile Asp Asn Pro His Ile Thr Tyr Thr Ala Arg Val Pro Val
 660 665 670
 Asp Val His Glu Tyr Asn Leu Thr His Leu Gln Pro Ser Thr Asp Tyr
 675 680 685
 Glu Val Cys Leu Thr Val Ser Asn Ile His Gln Gln Thr Gln Lys Ser
 690 695 700
 Cys Val Asn Val Thr Thr Lys Asn Ala Ala Phe Ala Val Asp Ile Ser
 705 710 715 720
 Asp Gln Glu Thr Ser Thr Ala Leu Ala Ala Val Met Gly Ser Met Phe
 725 730 735
 Ala Val Ile Ser Leu Ala Ser Ile Ala Val Tyr Phe Ala Lys Arg Phe
 740 745 750
 Lys Arg Lys Asn Tyr His His Ser Leu Lys Lys Tyr Met Gln Lys Thr
 755 760 765
 Ser Ser Ile Pro Leu Asn Glu Leu Tyr Pro Pro Leu Ile Asn Leu Trp
 770 775 780
 Glu Gly Asp Ser Glu Lys Asp Lys Asp Gly Ser Ala Asp Thr Lys Pro
 785 790 795 800
 Thr Gln Val Asp Thr Ser Arg Ser Tyr Tyr Met Trp
 805 810

<210> 6
 <211> 716
 <212> PRT
 <213> Homo sapiens

<400> 6
 Met Ala Arg Met Ser Phe Val Ile Ala Ala Cys Gln Leu Val Leu Gly
 1 5 10 15
 Leu Leu Met Thr Ser Leu Thr Glu Ser Ser Ile Gln Asn Ser Glu Cys
 20 25 30
 Pro Gln Leu Cys Val Cys Glu Ile Arg Pro Trp Phe Thr Pro Gln Ser
 35 40 45
 Thr Tyr Arg Glu Ala Thr Thr Val Asp Cys Asn Asp Leu Arg Leu Thr
 50 55 60
 Arg Ile Pro Ser Asn Leu Ser Ser Asp Thr Gln Val Leu Leu Leu Gln
 65 70 75 80
 Ser Asn Asn Ile Ala Lys Thr Val Asp Glu Leu Gln Gln Leu Phe Asn
 85 90 95

Leu Thr Glu Leu Asp Phe Ser Gln Asn Asn Phe Thr Asn Ile Lys Glu
 100 105 110
 Val Gly Leu Ala Asn Leu Thr Gln Leu Thr Thr Leu His Leu Glu Glu
 115 120 125
 Asn Gln Ile Thr Glu Met Thr Asp Tyr Cys Leu Gln Asp Leu Ser Asn
 130 135 140
 Leu Gln Glu Leu Tyr Ile Asn His Asn Gln Ile Ser Thr Ile Ser Ala
 145 150 155 160
 His Ala Phe Ala Gly Leu Lys Asn Leu Leu Arg Leu His Leu Asn Ser
 165 170 175
 Asn Lys Leu Lys Val Ile Asp Ser Arg Trp Phe Asp Ser Thr Pro Asn
 180 185 190
 Leu Glu Ile Leu Met Ile Gly Glu Asn Pro Val Ile Gly Ile Leu Asp
 195 200 205
 Met Asn Phe Lys Pro Leu Ala Asn Leu Arg Ser Leu Val Leu Ala Gly
 210 215 220
 Met Tyr Leu Thr Asp Ile Pro Gly Asn Ala Leu Val Gly Leu Asp Ser
 225 230 235 240
 Leu Glu Ser Leu Ser Phe Tyr Asp Asn Lys Leu Val Lys Val Pro Gln
 245 250 255
 Leu Ala Leu Gln Lys Val Pro Asn Leu Lys Phe Leu Asp Leu Asn Lys
 260 265 270
 Asn Pro Ile His Lys Ile Gln Glu Gly Asp Phe Lys Asn Met Leu Arg
 275 280 285
 Leu Lys Glu Leu Gly Ile Asn Asn Met Gly Glu Leu Val Ser Val Asp
 290 295 300
 Arg Tyr Ala Leu Asp Asn Leu Pro Glu Leu Thr Lys Leu Glu Ala Thr
 305 310 315 320
 Asn Asn Pro Lys Leu Ser Tyr Ile His Arg Leu Ala Phe Arg Ser Val
 325 330 335
 Pro Ala Leu Glu Ser Leu Met Leu Asn Asn Asn Ala Leu Asn Ala Ile
 340 345 350
 Tyr Gln Lys Thr Val Glu Ser Leu Pro Asn Leu Arg Glu Ile Ser Ile
 355 360 365
 His Ser Asn Pro Leu Arg Cys Asp Cys Val Ile His Trp Ile Asn Ser
 370 375 380
 Asn Lys Thr Asn Ile Arg Phe Met Glu Pro Leu Ser Met Phe Cys Ala
 385 390 395 400
 Met Pro Pro Glu Tyr Lys Gly His Gln Val Lys Glu Val Leu Ile Gln
 405 410 415

Asp Ser Ser Glu Gln Cys Leu Pro Met Ile Ser His Asp Ser Phe Pro
 420 425 430
 Asn Arg Leu Asn Val Asp Ile Gly Thr Thr Val Phe Leu Asp Cys Arg
 435 440 445
 Ala Met Ala Glu Pro Glu Pro Glu Ile Tyr Trp Val Thr Pro Ile Gly
 450 455 460
 Asn Lys Ile Thr Val Glu Thr Leu Ser Asp Lys Tyr Lys Leu Ser Ser
 465 470 475 480
 Glu Gly Thr Leu Glu Ile Ser Asn Ile Gln Ile Glu Asp Ser Gly Arg
 485 490 495
 Tyr Thr Cys Val Ala Gln Asn Val Gln Gly Ala Asp Thr Arg Val Ala
 500 505 510
 Thr Ile Lys Val Asn Gly Thr Leu Leu Asp Gly Thr Gln Val Leu Lys
 515 520 525
 Ile Tyr Val Lys Gln Thr Glu Ser His Ser Ile Leu Val Ser Trp Lys
 530 535 540
 Val Asn Ser Asn Val Met Thr Ser Asn Leu Lys Trp Ser Ser Ala Thr
 545 550 555 560
 Met Lys Ile Asp Asn Pro His Ile Thr Tyr Thr Ala Arg Val Pro Val
 565 570 575
 Asp Val His Glu Tyr Asn Leu Thr His Leu Gln Pro Ser Thr Asp Tyr
 580 585 590
 Glu Val Cys Leu Thr Val Ser Asn Ile His Gln Gln Thr Gln Lys Ser
 595 600 605
 Cys Val Asn Val Thr Thr Lys Asn Ala Ala Phe Ala Val Asp Ile Ser
 610 615 620
 Asp Gln Glu Thr Ser Thr Ala Leu Ala Ala Val Met Gly Ser Met Phe
 625 630 635 640
 Ala Val Ile Ser Leu Ala Ser Ile Ala Val Tyr Phe Ala Lys Arg Phe
 645 650 655
 Lys Arg Lys Asn Tyr His His Ser Leu Lys Lys Tyr Met Gln Lys Thr
 660 665 670
 Ser Ser Ile Pro Leu Asn Glu Leu Tyr Pro Pro Leu Ile Asn Leu Trp
 675 680 685
 Glu Gly Asp Ser Glu Lys Asp Lys Asp Gly Ser Ala Asp Thr Lys Pro
 690 695 700
 Thr Gln Val Asp Thr Ser Arg Ser Tyr Tyr Met Trp
 705 710 715